<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Management of new onset atrial fibrillation</title>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="Cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1120833" scheme="gov.nih.nlm.semanticType.phsu" label="Vital"/>
		<category term="C1565734" scheme="gov.nih.nlm.semanticType.phsu" label="ER"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="blockers, calcium channel"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="electrical cardioversion"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1722268" scheme="gov.nih.nlm.semanticType.orch" label="ACP"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0547070" scheme="gov.nih.nlm.semanticType.topp" label="ablation"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admission"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0082966" scheme="gov.nih.nlm.semanticType.phsu" label="ibutilide"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapies"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0206460" scheme="gov.nih.nlm.semanticType.phsu" label="enoxaparin"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<id>1057</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521215556"/>
			<id>206519</id>
			<summary>
				<section label="Important first steps" id="521215556">
					<fragment>A complete history and physical examination should be performed in all patients with new onset AF.</fragment>
				</section>
			</summary>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H448750704"/>
			<id>206524</id>
			<summary>
				<section label="INDICATIONS FOR URGENT CARDIOVERSION" id="448750704">
					<fragment>The presence of a preexcitation syndrome, which may lead to an extremely rapid ventricular rate due to the presence of an accessory pathway.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H448750704"/>
			<id>206525</id>
			<summary>
				<section label="INDICATIONS FOR URGENT CARDIOVERSION" id="448750704">
					<fragment>In a patient with any of these indications for urgent cardioversion, the need for restoration of normal sinus rhythm (NSR) takes precedence over the need for protection from thromboembolic risk.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H448750704"/>
			<id>206528</id>
			<summary>
				<section label="INDICATIONS FOR URGENT CARDIOVERSION" id="448750704">
					<fragment>Further, indiscriminate cardioversion may have dire consequences or be futile if the cause for the initiation of the problem is not at least in part corrected (eg, immediate cardioversion in a patient with pulmonary edema will be dangerous to the patient and may not be effective without diuresis, oxygen, blood pressure control and other measures).</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H448750704"/>
			<id>206530</id>
			<summary>
				<section label="INDICATIONS FOR URGENT CARDIOVERSION" id="448750704">
					<fragment>Cardioversion of patients with atrial fibrillation (AF) is discussed elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="Cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206531</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>When faced with a patient who presents with new onset atrial fibrillation (AF) (particularly if the ventricular response is rapid), there should be a quick assessment for an underlying cause, such as heart failure (HF), pulmonary problems, poorly controlled blood pressure, or hyperthyroidism.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206532</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>Therapy for a precipitating cause should be initiated prior to cardioversion in stable patients and may result in reversion to sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206533</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>The following tests, in addition to the electrocardiogram, should be performed on patients with new onset AF: Vital signs including oxygen saturation (in the ER setting and beyond).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1120833" scheme="gov.nih.nlm.semanticType.phsu" label="Vital"/>
			<category term="C1565734" scheme="gov.nih.nlm.semanticType.phsu" label="ER"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206535</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>These should be obtained even if there are no symptoms suggestive of hyperthyroidism (and if thyroid function has not been measured recently), since the risk of AF is increased up to threefold in patients with subclinical hyperthyroidism ).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206536</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>The latter disorder is characterized by low serum TSH (&lt;0.5 mU/L with the newer sensitive assays) and normal serum free T4.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206539</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>A transthoracic echocardiogram should be performed to screen for cardiac causes of new onset atrial fibrillation, even in the face of a normal physical examination.</fragment>
				</section>
			</summary>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206542</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>AF is rarely the only manifestation of an acute coronary syndrome, although AF with a rapid ventricular response and hypotension can provoke demand ischemia with or without angina.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H5"/>
			<id>206543</id>
			<summary>
				<section label="EVALUATION FOR AN UNDERLYING CAUSE" id="5">
					<fragment>We suggest evaluation of myocardial infarction with serial troponin measurements, especially in patients with electrocardiogram (ECG) changes, hypotension, symptoms, history, or additional risk factors.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H532809012"/>
			<id>206545</id>
			<summary>
				<section label="ANTICOAGULATION" id="532809012">
					<fragment>This section will address the role of antithrombotic therapy in patients with new onset AF.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H532809012"/>
			<id>206546</id>
			<summary>
				<section label="ANTICOAGULATION" id="532809012">
					<fragment>The larger discussions of anticoagulation surrounding cardioversion and recommendations for the use of long-term antithrombotic therapy in patients with more than one episode of atrial fibrillation (AF) are found elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710306792"/>
			<id>206548</id>
			<summary>
				<section label="Patients requiring delayed cardioversion" id="710306792">
					<fragment>In these patients, it is preferable to anticoagulate and use transesophageal echocardiography (TEE) to rule out left atrial thrombi.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710306792"/>
			<id>206551</id>
			<summary>
				<section label="Patients requiring delayed cardioversion" id="710306792">
					<fragment>While there is little published evidence that the risk of embolization after planned (either chemical or electric) cardioversion is greater than after spontaneous reversion, some of our authors and reviewers are concerned that delayed return of atrial mechanical function (atrial stunning) after electrical cardioversion could increase the risk of a thromboembolic event after this approach with cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710306792"/>
			<id>206556</id>
			<summary>
				<section label="Patients requiring delayed cardioversion" id="710306792">
					<fragment>When warfarin is chosen as the anticoagulant, the recommended target International Normalized Ratio (INR) is 2.5 (range 2.0 to 3.0).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710307197"/>
			<id>206559</id>
			<summary>
				<section label="Role of TEE" id="710307197">
					<fragment>This regimen may be of particular use in the patient who requires hospitalization or has an increased risk of hemorrhagic complications during prolonged anticoagulant therapy.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710307197"/>
			<id>206560</id>
			<summary>
				<section label="Role of TEE" id="710307197">
					<fragment>The ACUTE trial directly compared a TEE-guided strategy (anticoagulation with heparin immediately before TEE or with oral warfarin for five days [target INR 2.0 to 3.0] before TEE, followed by cardioversion and then warfarin for four weeks after cardioversion), with a conventional strategy (three weeks of anticoagulation before cardioversion, followed by four weeks of anticoagulation after cardioversion) in 1222 patients with AF of more than two days' duration who were undergoing electrical cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206564</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>With the exception of certain high-risk patients, the embolic risk appears to be very low if cardioversion is performed within two days of the onset of AF.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206566</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>The logic for doing so is that the risk of bleeding from anticoagulation is probably greater than the risk of embolization (particularly in those with CHADS2 scores of 0 or 1), and the risk of thromboembolic events from short duration of atrial fibrillation appears to be relatively low (but not zero).</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206568</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>In addition, our authors and reviewers differ on the approach to long-term anticoagulation in these patients, with some suggesting no oral anticoagulation for the first episode of AF (less than 48 hours duration) and others suggesting warfarin or a novel oral anticoagulant for patients with CHADS2/CHA2DS2-VASc scores of two or greater.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206569</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>Guidelines from the American College of Cardiology/American Heart Association and the American College of Chest Physicians suggest periprocedural heparin in patients with new onset AF of less than 48 hours duration, but make weak recommendations against the use of prolonged anticoagulation (three weeks).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206570</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>The 2011 European Society of Cardiology guidelines for the management of AF make a weak recommendation for periprocedural heparin in all such patients, as well as long-term oral anticoagulant in patients at high risk of stroke.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H526865111"/>
			<id>206571</id>
			<summary>
				<section label="Early cardioversion or spontaneous reversion" id="526865111">
					<fragment>Our authors and reviewers believe it is reasonable to defer cardioversion and start oral anticoagulation in selected patients with AF of less than 48 hours in whom cardioversion is planned.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206574</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>In patients with mild to moderate symptoms, concurrent with the initiation of the appropriate anticoagulation treatment, the initial therapy includes slowing the ventricular rate without an immediate strategy to restore sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206578</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>As noted above, this can be achieved with beta blockers, calcium channel blockers (primarily verapamil and diltiazem), and/or digoxin.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="blockers, calcium channel"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206579</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>Occasionally, intravenous (IV) amiodarone may be needed for patients with poor left ventricular function.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206581</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>Beta blockers or verapamil or diltiazem are the preferred drugs in the absence of heart failure (HF), since digoxin is less likely to control the ventricular rate during exercise (when vagal tone is low and sympathetic tone is high), has little ability to terminate the arrhythmia, and often does not slow the heart rate in patients with recurrent atrial fibrillation (AF).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206583</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>Digoxin is the preferred drug only in patients with AF due to HF.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206584</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>In addition to the direct vagotonic effect of digoxin on the atrioventricular (AV) node (which may require several hours to become apparent), the improvement in left ventricular function and systemic hemodynamics result in withdrawal of sympathetic tone and a further decrease in the ventricular rate.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206586</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>Digoxin can also be used in patients who cannot take or who respond inadequately to beta blockers or calcium channel blockers.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206587</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>The effect of digoxin is additive to both of these drugs.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206590</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>IV AV nodal blockers, in particular digoxin and verapamil, are contraindicated in patients with atrial fibrillation and preexcitation.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H8"/>
			<id>206598</id>
			<summary>
				<section label="INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS" id="8">
					<fragment>On the other hand, a calcium channel blocker is preferred in patients with chronic lung disease.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206601</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>The next step after control of the ventricular rate in patients with recent onset atrial fibrillation (AF), who are hemodynamically stable (with only mild to moderate symptoms), is deciding whether an attempt will be made to cardiovert the patient and if so when.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206602</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>We believe that most patients with symptomatic new onset atrial fibrillation should have at least one attempt at cardioversion (either electrical or chemical) to sinus rhythm, particularly after reversible causes have been identified and corrected.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206604</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>cardioversion will likely improve symptom status, particularly in young people.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206605</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>Circumstances in which it is reasonable to not attempt cardioversion in a patient with new onset AF include: Patients who are completely asymptomatic, particularly those who are very elderly (&gt;80 years) with multiple comorbidities, where risks of undergoing cardioversion and/or pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206608</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>There is a low risk of systemic embolization if the duration of the arrhythmia is 24 hours or less (and the risks are acceptable up to 48 hours) and there are no cardiac abnormalities (particularly mitral valve disease or significant left ventricular enlargement due to a cardiomyopathy) on transthoracic echocardiography.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206609</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>Most patients with new onset AF of longer than 48 hours duration should have cardioversion postponed.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206612</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>For patients with paroxysmal episodes of atrial fibrillation, drug therapy is preferred if they will have sinus rhythm maintained with long-term antiarrhythmic drug therapy, and as patients with paroxysmal atrial fibrillation will likely convert anyway with or without electrical cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="electrical cardioversion"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H9"/>
			<id>206614</id>
			<summary>
				<section label="CARDIOVERSION" id="9">
					<fragment>In some patients, antiarrhythmic drugs are administered prior to cardioversion to increase the chance of successful reversion and to prevent early, intermediate, and late recurrence ).</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214080"/>
			<id>206616</id>
			<summary>
				<section label="Antiarrhythmic therapy after reversion to sinus rhythm" id="521214080">
					<fragment>We agree with the American Association of Family Physicians/American College of Physicians (AAFP/ACP) guideline recommendation that maintenance antiarrhythmic drug therapy not be routinely used after cardioversion in patients with newly detected AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1722268" scheme="gov.nih.nlm.semanticType.orch" label="ACP"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H710307544"/>
			<id>206622</id>
			<summary>
				<section label="Spontaneous reversion of AF" id="710307544">
					<fragment>The optimal antithrombotic therapy after spontaneous cardioversion of a first episode of AF (lasting less than 48 hours) in patients without structural heart disease is discussed above.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214863"/>
			<id>206624</id>
			<summary>
				<section label="INDICATIONS FOR HOSPITALIZATION" id="521214863">
					<fragment>Many patients with new onset atrial fibrillation (AF), particularly those without spontaneous reversion, have often been admitted to the hospital.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214863"/>
			<id>206629</id>
			<summary>
				<section label="INDICATIONS FOR HOSPITALIZATION" id="521214863">
					<fragment>Possible indications for hospitalization in patients with new onset AF are: Initiation of heparin or other anticoagulant therapy.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214863"/>
			<id>206630</id>
			<summary>
				<section label="INDICATIONS FOR HOSPITALIZATION" id="521214863">
					<fragment>Patients in whom ablation of an accessory pathway is being considered, particularly if the AF was highly symptomatic and associated with hemodynamic collapse and rapid ventricular response rate.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0547070" scheme="gov.nih.nlm.semanticType.topp" label="ablation"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214863"/>
			<id>206636</id>
			<summary>
				<section label="INDICATIONS FOR HOSPITALIZATION" id="521214863">
					<fragment>The elderly are more likely to have comorbidities that can complicate drug management in the treatment of atrial fibrillation, whether it be rate control or rhythm control approaches.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214870"/>
			<id>206640</id>
			<summary>
				<section label="DISCHARGE FROM THE EMERGENCY ROOM" id="521214870">
					<fragment>For those patients who do not have one of the above clear indications for hospitalization, an important initial issue is whether patients presenting with new onset atrial fibrillation (AF) (less than 48 hours duration) can be managed (including cardioversion) in the emergency department or an observational unit and then discharged.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214870"/>
			<id>206641</id>
			<summary>
				<section label="DISCHARGE FROM THE EMERGENCY ROOM" id="521214870">
					<fragment>This issue was addressed in a study of 289 such patients who were stable, did not have heart disease, and did not have another indication for hospital admission.</fragment>
				</section>
			</summary>
			<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admission"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214870"/>
			<id>206645</id>
			<summary>
				<section label="DISCHARGE FROM THE EMERGENCY ROOM" id="521214870">
					<fragment>Similar results were noted in another report of 51 patients who underwent attempted pharmacologic cardioversion with intravenous ibutilide, followed by electrical reversion if AF was still present.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0082966" scheme="gov.nih.nlm.semanticType.phsu" label="ibutilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H521214870"/>
			<id>206647</id>
			<summary>
				<section label="DISCHARGE FROM THE EMERGENCY ROOM" id="521214870">
					<fragment>Thus, emergency department or observational unit treatment of new onset AF in clinically stable patients, who have no other important comorbidities such as underlying structural heart disease, is safe and cost-effective.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234550"/>
			<id>206649</id>
			<summary>
				<section label="UP" id="461234550">
					<fragment>Routine follow-up after an episode of acute atrial fibrillation is necessary to evaluate the safety and efficacy of antiarrhythmic and anticoagulant therapies, to reassess the need for these therapies, and to assess the functional status of the patient.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206661</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>The early steps in the management of a patient with new onset atrial fibrillation (AF) involve an assessment of the need for cardioversion, rate slowing therapy, and antithrombotic therapy.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206663</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Urgent or emergent cardioversion should be considered for patients with active ischemia, significant hypotension, severe heart failure, or the presence of a preexcitation syndrome associated with rapid conduction using the accessory pathway.(See.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206666</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Most patients with symptomatic new onset atrial fibrillation should have at least one attempt at cardioversion (either electrical or chemical) to sinus rhythm, particularly after reversible causes have been identified and corrected.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206668</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Most patients with new onset AF who have sinus rhythm restored do not need maintenance antiarrhythmic drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206669</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Our specific recommendations are as follows: We recommend rate control to improve symptoms and to reduce the risk of tachycardia-mediated cardiomyopathy for all patients who do not require urgent or emergent cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206671</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Beta blockers and nondihydropyridine calcium channel blockers are preferred as first-line agents in most patients.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206673</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>For patients with AF less than 48 hours in duration, the use of periprocedural heparin (or enoxaparin) to reduce the risk of embolization can be considered.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0206460" scheme="gov.nih.nlm.semanticType.phsu" label="enoxaparin"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206675</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>The decision to start long-term oral anticoagulation in these patients should be made based on an assessment of the long-term risk of embolization based on the CHADS2 score.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206676</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>For patients with AF of longer than 48 hours duration, we recommend four weeks of therapeutic oral anticoagulation prior to cardioversion, as opposed to immediate cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206677</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Transesophageal echocardiography-based (TEE) screening for the presence of atrial thrombi is recommended among patients with AF of recent onset (but more than 48 hours or unknown duration) if semi-urgent cardioversion is necessary.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screening"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1057#H461234558"/>
			<id>206679</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="461234558">
					<fragment>Possible indications for hospitalization in patients with new onset AF include (but are not limited to).</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations</title>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0053672" scheme="gov.nih.nlm.semanticType.orch" label="bpm"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0360692" scheme="gov.nih.nlm.semanticType.phsu" label="Class I antiarrhythmic"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="Antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="Dofetilide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0085251" scheme="gov.nih.nlm.semanticType.phsu" label="encainide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="IC"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="Dronedarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmics"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0044225" scheme="gov.nih.nlm.semanticType.phsu" label="Flec"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308714" scheme="gov.nih.nlm.semanticType.phsu" label="concept"/>
		<category term="C1569181" scheme="gov.nih.nlm.semanticType.aapp" label="SL"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<id>1035</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148627</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>There are three settings in which a rhythm control strategy for the maintenance of sinus rhythm should be considered: Persistent symptoms (palpitations, dyspnea, lightheadedness, angina, syncope, and heart failure) despite adequate rate control.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148631</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>We consider cardioversion to sinus rhythm in most patients, particularly younger patients, with a first-detected episode of atrial fibrillation (AF) in whom the arrhythmia is of recent onset and the risk for recurrence appears to be low.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148632</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>Maintenance antiarrhythmic drug therapy is not routinely used after cardioversion in patients with newly detected AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850711"/>
			<id>148640</id>
			<summary>
				<section label="Addressing precipitating factors" id="523850711">
					<fragment>Maintenance antiarrhythmic drug therapy is not recommended after cardioversion in a patient with a transient or reversible cause (such as cardiac surgery, pericarditis, or pulmonary embolism).</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148650</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>This therapy is continued while the patient is in sinus rhythm to protect against a rapid ventricular rate (greater than 110 bpm) should AF recur.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0053672" scheme="gov.nih.nlm.semanticType.orch" label="bpm"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148651</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>A beta blocker, or rate-slowing calcium channel blocker such as verapamil or diltiazem, is often used if there are no contraindications, since the withdrawal of vagal tone and increase in sympathetic tone with exercise often render digoxin relatively ineffective for controlling the heart rate.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148654</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>On the other hand, digoxin is often used in patients with AF associated with systolic heart failure because of its beneficial effect on symptom control.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148655</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>Such patients are also typically treated with a beta blocker because of the associated improvement in survival.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148656</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>The negative inotropic activity of calcium channel blockers makes them less desirable in such patients.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148658</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>Class I antiarrhythmic drugs, such as flecainide, may suppress most, but not all, reentrant circuits.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0360692" scheme="gov.nih.nlm.semanticType.phsu" label="Class I antiarrhythmic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H780615209"/>
			<id>148662</id>
			<summary>
				<section label="Restoration of sinus rhythm" id="780615209">
					<fragment>Many patients with AF in whom a rhythm control strategy is chosen will need sinus rhythm restored prior to the initiation of long-term antiarrhythmic drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148669</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Amiodarone, dofetilide, flecainide, propafenone, sotalol, and less commonly dronedarone are the drugs we recommend to maintain sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148671</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>The following points regarding antiarrhythmic drugs should be kept in mind in choosing therapy: Compared to other agents, amiodarone is associated with the greatest likelihood of maintaining sinus rhythm, but also with the highest risk of long-term complications.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148672</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Quinidine, procainamide, and disopyramide are no longer recommended for patients with AF, except perhaps in patients with vagally mediated atrial fibrillation (AF), as there are more effective drugs and due to extracardiac side effects as well as the concern about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148673</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148674</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Of course beta blockers may have already been initiated to slow the ventricular rate in AF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148676</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>We believe it is prudent to obtain a two-dimensional echocardiogram to screen for structural heart disease (eg, left ventricular systolic dysfunction, left ventricular hypertrophy, or valvular heart disease).</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148679</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>As examples, our experts rarely use dofetilide for paroxysmal AF and infrequently choose dronedarone for persistent AF due to reduced efficacy compared with amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148681</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>The 2010 European Society of Cardiology and the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines suggest that, because of its long-lasting anticholinergic activity, disopyramide may be considered in patients with vagally-induced AF (eg, occurring most often in athletic young men with slow heart rates during rest or sleep), as long as the patient does not have prostatism or glaucoma.</fragment>
				</section>
			</summary>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148686</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>For patients with adrenergically-mediated AF (eg, occurring during exercise or other activity), we suggest beta blockers as first-line therapy, followed by sotalol and amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148687</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="Antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148691</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>Patients without structural heart disease include those with hypertension who do not have left ventricular hypertrophy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148692</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>The author and reviewers of this topic generally select flecainide as the first antiarrhythmic drug for these patients due to its relatively good side effect profile, efficacy, and ease of use.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148693</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In these patients, flecainide, propafenone, amiodarone, dronedarone, sotalol, and dofetilide are superior to placebo for maintaining sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148694</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>For those patients in whom flecainide will not be used as the preferred agent, the following points can influence the choice of antiarrhythmic drug in patients without structural heart disease: In the Canadian Trial of Atrial fibrillation, AFFIRM, and the SAFE-T randomized trials, amiodarone was more effective than flecainide, propafenone, or sotalol (which have nearly equivalent efficacy to each other), but has a significantly higher rate of adverse side effects.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148695</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In a meta-analysis of trials where the effect of amiodarone versus dronedarone was estimated with the use of indirect comparison and normal logistic meta-analysis models, amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148698</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In the EMERALD trial, Dofetilide had a somewhat better efficacy than sotalol.</fragment>
				</section>
			</summary>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="Dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148700</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>Some cardiologists prefer to use low-dose amiodarone (200 mg per day) in preference to flecainide, sotalol, or dronedarone for two principal reasons: greater efficacy than sotalol and dronedarone, and a very low incidence of torsades de pointes.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148704</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>Amiodarone, sotalol, and dofetilide are the most commonly recommended first-line drugs in patients with structural heart disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148707</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>These drugs (with the exception of dronedarone) were used for initial therapy in almost 70 percent of patients in AFFIRM, 88 percent of whom had organic heart disease and/or hypertension.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148708</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>Amiodarone was significantly more effective than sotalol in the CTAF, AFFIRM, and SAFE-T trials.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148709</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>However, in SAFE-T, sotalol was as effective as amiodarone in the subgroup of patients with coronary heart disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148710</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>In patients with coronary heart disease who do not have heart failure, sotalol, dronedarone, dofetilide, and amiodarone are acceptable choices.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148713</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>In the Cardiac Arrhythmia Suppression Trial (CAST) of patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction, flecainide increased mortality compared to placebo.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148714</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>Although propafenone was not used in CAST and may not have the same potential for proarrhythmia as flecainide and encainide, it cannot be recommended in patients with underlying heart disease.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0085251" scheme="gov.nih.nlm.semanticType.phsu" label="encainide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148715</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>The extension of this concern to structural heart disease other than coronary artery disease stems in part from the flecainide clinical and safety database, which was used in a retrospective study demonstrating that the presence of structural heart disease including valvular heart disease, congenital heart disease, and cardiomyopathies lead to an alarming increase in proarrhythmia and death.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148716</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Amiodarone and dofetilide, are used in patients with AF and heart failure (HF) or those with a left ventricular ejection fraction less than 35 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148717</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Our authors and reviewers are more comfortable using dofetilide in this setting with an implantable defibrillator in place or in younger patients with less severe impairment of left ventricular systolic function.</fragment>
				</section>
			</summary>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148719</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Sotalol, propafenone, and flecainide should not be used in patients with heart failure, due to studies showing an increase in mortality with these agents.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H13"/>
			<id>148720</id>
			<summary>
				<section label="Left ventricular hypertrophy" id="13">
					<fragment>Patients with significant left ventricular hypertrophy (defined as left ventricular wall thickness greater 1.4 cm for the purposes of this discussion) due to hypertension, hypertrophic cardiomyopathy, or aortic stenosis have underlying subendocardial ischemia and electrophysiologic abnormalities.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H13"/>
			<id>148722</id>
			<summary>
				<section label="Left ventricular hypertrophy" id="13">
					<fragment>Sotalol, flecainide and propafenone are thought to have a significant arrhythmic risk in patients with left ventricular hypertrophy (LVH).</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148725</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148726</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>Although some have suggested that combination antiarrhythmic drug therapy (eg, a class IC agent with sotalol or amiodarone, often in lower doses) may be an alternative, there are limited data to support such an approach and the patient may be exposed to a greater risk of proarrhythmia and other side effects.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="IC"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148727</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>As a result, combination antiarrhythmic drug therapy is not recommended.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148733</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Outpatient initiation of antiarrhythmic drug therapy with the following agents may be considered: Flecainide or propafenone in patients in sinus rhythm who have no underlying structural heart disease, normal baseline QT intervals, and no profound bradycardia or suspected sinus or atrioventricular (AV) node dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148734</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Amiodarone or dronedarone in selected patients who have no other risk factors for torsades de pointes (eg, hypokalemia, hypomagnesemia) or sinus node dysfunction or AV conduction disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148735</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Dronedarone and amiodarone are the only two drugs that can be initiated in outpatients while in atrial fibrillation.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="Dronedarone"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148736</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Patients with an implantable cardioverter-defibrillator (ICD) represent another group in which outpatient initiation of therapy can be tried, since the ICD provides protection against the risks associated with bradyarrhythmias and tachyarrhythmias.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148738</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>The initiation of antiarrhythmic drugs in patients with paroxysmal AF while they are in sinus rhythm is also associated with some risk.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148741</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Inpatient initiation with continuous telemetry of higher-risk drugs such as dofetilide and sotalol is typically done over a course of three days, which encompasses five half-lives allowing for achievement of steady-state plasma concentrations.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148743</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>Some patients will elect to continue drug therapy (and, in some cases, occasional cardioversion) because the arrhythmia burden has been substantially reduced as evidenced by episodes that are less frequent, shorter, or associated with milder symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148744</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>Nonpharmacologic therapies are another option in such patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148745</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>If a patient has unacceptable recurrent AF on one antiarrhythmic drug, the drug is discontinued and another (and on rare occasion a third) agent is tried.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855015"/>
			<id>148752</id>
			<summary>
				<section label="related arrhythmias and mortality" id="523855015">
					<fragment>Compared to controls, the use of the class IA antiarrhythmics quinidine and disopyramide (odds ratio 2.39, 95% CI 1.03-5.59) or sotalol (2.47, 95% CI 1.2-5.05) was associated with increased all-cause mortality, whereas the use of amiodarone, dronedarone, and dofetilide was not (odds ratios were not calculated for flecainide or propafenone).</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmics"/>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148754</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>All of the antiarrhythmic drugs used to maintain sinus rhythm have the potential to increase ectopy or induce or aggravate monomorphic ventricular tachycardia (VT), torsades de pointes, or ventricular fibrillation (VF);</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148756</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>In addition to its baseline potential to predispose the patient to proarrhythmia, a drug that is initially safe may become proarrhythmic when the patient develops coronary heart disease or heart failure or is treated with other medications that in combination may be arrhythmogenic.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148757</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>Thus, the patient should be alerted to the potential significance of symptoms such as syncope and dyspnea and warned about the use of noncardiac drugs that can prolong the QT interval.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148761</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>For type IA or type III drugs, with the possible exception of amiodarone, the corrected QT interval in sinus rhythm should remain below 520 milliseconds.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148763</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>During follow-up, serum creatinine, potassium, and magnesium concentrations should be monitored periodically because proarrhythmia is increased by renal insufficiency, which can lead to drug accumulation, hyperkalemia, and hypermagnesemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148765</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>In comparison, amiodarone is metabolized in the liver and dose adjustment is probably necessary in patients with hepatic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855029"/>
			<id>148766</id>
			<summary>
				<section label="Bradyarrhythmia" id="523855029">
					<fragment>Amiodarone and dronedarone can cause both sinus bradycardia and AV nodal block, with an overall incidence of bradycardic events of about 5 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855029"/>
			<id>148767</id>
			<summary>
				<section label="Bradyarrhythmia" id="523855029">
					<fragment>Sotalol, like other beta blockers, can also cause bradycardia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H266072426"/>
			<id>148777</id>
			<summary>
				<section label="term therapy" id="266072426">
					<fragment>This concept was tested in the Flec-SL non-inferiority trial, which randomly assigned 554 patients with persistent AF and who were intended to undergo cardioversion to either four weeks or six months of flecainide (200 to 300 mg per day).</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0044225" scheme="gov.nih.nlm.semanticType.phsu" label="Flec"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308714" scheme="gov.nih.nlm.semanticType.phsu" label="concept"/>
			<category term="C1569181" scheme="gov.nih.nlm.semanticType.aapp" label="SL"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148782</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>Patients with severe heart failure (HF) (generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks) or those with an ejection fraction of &lt;35 percent should not receive dronedarone.</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148783</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The Permanent Atrial fibriLLAtion outcome Study (PALLAS) was designed to test the hypothesis that dronedarone would improve major outcomes in 10,000 patients with permanent AF, over 70 percent of whom had New York Heart Association heart failure class I to III or left ventricular systolic dysfunction at baseline.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148787</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The study was stopped early (3236 patients enrolled), after a significantly increased risk (Hazard Ratio 2.29, 95% CI 1.34-3.94) of cardiovascular events (cardiovascular death, myocardial infarction, stroke and systemic embolism) was observed in the dronedarone arm.</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148788</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The individual secondary end points of stroke, death from cardiovascular causes, and hospitalization for heart failure were also significantly increased in the dronedarone group.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148790</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>In addition, the USFDA now recommends that people taking the drug should have an electrocardiogram every three months to make sure that AF has not become permanent.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148791</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>For patients taking dronedarone, routine monitoring of lung and liver function is not mandated by the USFDA;</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148793</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>Our recommendations for the use of antiarrhythmic drugs to maintain sinus rhythm in patients with AF are generally in agreement with the American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines on AF and the 2010 European Society of Cardiology guidelines on AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148794</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>The 2006 American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend propafenone, flecainide, and sotalol as first-line drugs to maintain sinus rhythm after cardioversion in patients without structural heart disease;</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148795</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>amiodarone and dofetilide can also be given as second-line agents.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148797</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>These drugs are generally better tolerated and perhaps safer than the class IA drugs, such as quinidine, which were widely used in the past.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148798</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>Because of concerns about toxicity, the ACC/AHA/ESC guidelines recommend that the use of amiodarone as a first-line therapy for maintenance of sinus rhythm should be reserved for patients with heart failure, moderate-to-severe systolic dysfunction, or hypertension with substantial left ventricular hypertrophy.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148808</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For those patients with atrial fibrillation (AF) in whom a rhythm-control strategy is chosen, the principal goal is to reduce symptoms by decreasing the frequency and duration of episodes.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148810</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>The following points should be kept in mind when considering antiarrhythmic drug therapy to maintain sinus rhythm in patients with AF: Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148811</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Compared to placebo, amiodarone, sotalol, dofetilide, dronedarone, flecainide, and propafenone are effective for the maintenance of sinus rhythm, but maintenance rates at one year are significantly less than 75 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148812</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Amiodarone is consistently more effective than the other antiarrhythmic drugs.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148815</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Although a drug may be shown to significantly prolong the time to recurrence of AF in a clinical trial, individual patients may experience no benefit or experience a dramatic reduction in AF frequency.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148822</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>We make the following recommendations for the choice of antiarrhythmic drug to maintain sinus rhythm in patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148823</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with no structural heart disease and no apparent risk for drug-induced bradycardia or tachycardia, we suggest flecainide as the preferred antiarrhythmic drug.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148826</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with coronary artery disease who do not have advanced heart failure, we suggest dronedarone or sotalol in preference to amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148827</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Amiodarone is a reasonable choice in patients who prefer its greater efficacy despite its worse extracardiac side-effect profile.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148828</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with heart failure, we suggest amiodarone in preference to dofetilide.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148829</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Flecainide, propafenone, dronedarone, and sotalol are contraindicated in these patients.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148830</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with left ventricular hypertrophy, either amiodarone or dronedarone is generally preferred to other antiarrhythmic agents.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations</title>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0053672" scheme="gov.nih.nlm.semanticType.orch" label="bpm"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0360692" scheme="gov.nih.nlm.semanticType.phsu" label="Class I antiarrhythmic"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="Antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="Dofetilide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0085251" scheme="gov.nih.nlm.semanticType.phsu" label="encainide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="IC"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="Dronedarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmics"/>
		<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0044225" scheme="gov.nih.nlm.semanticType.phsu" label="Flec"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308714" scheme="gov.nih.nlm.semanticType.phsu" label="concept"/>
		<category term="C1569181" scheme="gov.nih.nlm.semanticType.aapp" label="SL"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
		<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
		<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<id>1035</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148627</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>There are three settings in which a rhythm control strategy for the maintenance of sinus rhythm should be considered: Persistent symptoms (palpitations, dyspnea, lightheadedness, angina, syncope, and heart failure) despite adequate rate control.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148631</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>We consider cardioversion to sinus rhythm in most patients, particularly younger patients, with a first-detected episode of atrial fibrillation (AF) in whom the arrhythmia is of recent onset and the risk for recurrence appears to be low.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577201755"/>
			<id>148632</id>
			<summary>
				<section label="INDICATIONS" id="577201755">
					<fragment>Maintenance antiarrhythmic drug therapy is not routinely used after cardioversion in patients with newly detected AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850711"/>
			<id>148640</id>
			<summary>
				<section label="Addressing precipitating factors" id="523850711">
					<fragment>Maintenance antiarrhythmic drug therapy is not recommended after cardioversion in a patient with a transient or reversible cause (such as cardiac surgery, pericarditis, or pulmonary embolism).</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148650</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>This therapy is continued while the patient is in sinus rhythm to protect against a rapid ventricular rate (greater than 110 bpm) should AF recur.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0053672" scheme="gov.nih.nlm.semanticType.orch" label="bpm"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148651</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>A beta blocker, or rate-slowing calcium channel blocker such as verapamil or diltiazem, is often used if there are no contraindications, since the withdrawal of vagal tone and increase in sympathetic tone with exercise often render digoxin relatively ineffective for controlling the heart rate.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148654</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>On the other hand, digoxin is often used in patients with AF associated with systolic heart failure because of its beneficial effect on symptom control.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148655</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>Such patients are also typically treated with a beta blocker because of the associated improvement in survival.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148656</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>The negative inotropic activity of calcium channel blockers makes them less desirable in such patients.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523851208"/>
			<id>148658</id>
			<summary>
				<section label="AV nodal blocker therapy" id="523851208">
					<fragment>Class I antiarrhythmic drugs, such as flecainide, may suppress most, but not all, reentrant circuits.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0360692" scheme="gov.nih.nlm.semanticType.phsu" label="Class I antiarrhythmic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H780615209"/>
			<id>148662</id>
			<summary>
				<section label="Restoration of sinus rhythm" id="780615209">
					<fragment>Many patients with AF in whom a rhythm control strategy is chosen will need sinus rhythm restored prior to the initiation of long-term antiarrhythmic drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148669</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Amiodarone, dofetilide, flecainide, propafenone, sotalol, and less commonly dronedarone are the drugs we recommend to maintain sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148671</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>The following points regarding antiarrhythmic drugs should be kept in mind in choosing therapy: Compared to other agents, amiodarone is associated with the greatest likelihood of maintaining sinus rhythm, but also with the highest risk of long-term complications.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148672</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Quinidine, procainamide, and disopyramide are no longer recommended for patients with AF, except perhaps in patients with vagally mediated atrial fibrillation (AF), as there are more effective drugs and due to extracardiac side effects as well as the concern about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148673</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148674</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Of course beta blockers may have already been initiated to slow the ventricular rate in AF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148676</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>We believe it is prudent to obtain a two-dimensional echocardiogram to screen for structural heart disease (eg, left ventricular systolic dysfunction, left ventricular hypertrophy, or valvular heart disease).</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148679</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>As examples, our experts rarely use dofetilide for paroxysmal AF and infrequently choose dronedarone for persistent AF due to reduced efficacy compared with amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148681</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>The 2010 European Society of Cardiology and the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines suggest that, because of its long-lasting anticholinergic activity, disopyramide may be considered in patients with vagally-induced AF (eg, occurring most often in athletic young men with slow heart rates during rest or sleep), as long as the patient does not have prostatism or glaucoma.</fragment>
				</section>
			</summary>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148686</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>For patients with adrenergically-mediated AF (eg, occurring during exercise or other activity), we suggest beta blockers as first-line therapy, followed by sotalol and amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850628"/>
			<id>148687</id>
			<summary>
				<section label="SELECTING AN ANTIARRHYTHMIC DRUG" id="523850628">
					<fragment>Antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="Antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148691</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>Patients without structural heart disease include those with hypertension who do not have left ventricular hypertrophy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148692</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>The author and reviewers of this topic generally select flecainide as the first antiarrhythmic drug for these patients due to its relatively good side effect profile, efficacy, and ease of use.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148693</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In these patients, flecainide, propafenone, amiodarone, dronedarone, sotalol, and dofetilide are superior to placebo for maintaining sinus rhythm.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148694</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>For those patients in whom flecainide will not be used as the preferred agent, the following points can influence the choice of antiarrhythmic drug in patients without structural heart disease: In the Canadian Trial of Atrial fibrillation, AFFIRM, and the SAFE-T randomized trials, amiodarone was more effective than flecainide, propafenone, or sotalol (which have nearly equivalent efficacy to each other), but has a significantly higher rate of adverse side effects.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148695</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In a meta-analysis of trials where the effect of amiodarone versus dronedarone was estimated with the use of indirect comparison and normal logistic meta-analysis models, amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148698</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>In the EMERALD trial, Dofetilide had a somewhat better efficacy than sotalol.</fragment>
				</section>
			</summary>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="Dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H9"/>
			<id>148700</id>
			<summary>
				<section label="AF without structural heart disease" id="9">
					<fragment>Some cardiologists prefer to use low-dose amiodarone (200 mg per day) in preference to flecainide, sotalol, or dronedarone for two principal reasons: greater efficacy than sotalol and dronedarone, and a very low incidence of torsades de pointes.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148704</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>Amiodarone, sotalol, and dofetilide are the most commonly recommended first-line drugs in patients with structural heart disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148707</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>These drugs (with the exception of dronedarone) were used for initial therapy in almost 70 percent of patients in AFFIRM, 88 percent of whom had organic heart disease and/or hypertension.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148708</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>Amiodarone was significantly more effective than sotalol in the CTAF, AFFIRM, and SAFE-T trials.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H10"/>
			<id>148709</id>
			<summary>
				<section label="AF associated with structural heart disease" id="10">
					<fragment>However, in SAFE-T, sotalol was as effective as amiodarone in the subgroup of patients with coronary heart disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148710</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>In patients with coronary heart disease who do not have heart failure, sotalol, dronedarone, dofetilide, and amiodarone are acceptable choices.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148713</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>In the Cardiac Arrhythmia Suppression Trial (CAST) of patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction, flecainide increased mortality compared to placebo.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148714</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>Although propafenone was not used in CAST and may not have the same potential for proarrhythmia as flecainide and encainide, it cannot be recommended in patients with underlying heart disease.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0085251" scheme="gov.nih.nlm.semanticType.phsu" label="encainide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H11"/>
			<id>148715</id>
			<summary>
				<section label="Coronary heart disease" id="11">
					<fragment>The extension of this concern to structural heart disease other than coronary artery disease stems in part from the flecainide clinical and safety database, which was used in a retrospective study demonstrating that the presence of structural heart disease including valvular heart disease, congenital heart disease, and cardiomyopathies lead to an alarming increase in proarrhythmia and death.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148716</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Amiodarone and dofetilide, are used in patients with AF and heart failure (HF) or those with a left ventricular ejection fraction less than 35 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148717</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Our authors and reviewers are more comfortable using dofetilide in this setting with an implantable defibrillator in place or in younger patients with less severe impairment of left ventricular systolic function.</fragment>
				</section>
			</summary>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H12"/>
			<id>148719</id>
			<summary>
				<section label="Heart failure" id="12">
					<fragment>Sotalol, propafenone, and flecainide should not be used in patients with heart failure, due to studies showing an increase in mortality with these agents.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H13"/>
			<id>148720</id>
			<summary>
				<section label="Left ventricular hypertrophy" id="13">
					<fragment>Patients with significant left ventricular hypertrophy (defined as left ventricular wall thickness greater 1.4 cm for the purposes of this discussion) due to hypertension, hypertrophic cardiomyopathy, or aortic stenosis have underlying subendocardial ischemia and electrophysiologic abnormalities.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H13"/>
			<id>148722</id>
			<summary>
				<section label="Left ventricular hypertrophy" id="13">
					<fragment>Sotalol, flecainide and propafenone are thought to have a significant arrhythmic risk in patients with left ventricular hypertrophy (LVH).</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148725</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148726</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>Although some have suggested that combination antiarrhythmic drug therapy (eg, a class IC agent with sotalol or amiodarone, often in lower doses) may be an alternative, there are limited data to support such an approach and the patient may be exposed to a greater risk of proarrhythmia and other side effects.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="IC"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H16"/>
			<id>148727</id>
			<summary>
				<section label="resistant AF" id="16">
					<fragment>As a result, combination antiarrhythmic drug therapy is not recommended.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148733</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Outpatient initiation of antiarrhythmic drug therapy with the following agents may be considered: Flecainide or propafenone in patients in sinus rhythm who have no underlying structural heart disease, normal baseline QT intervals, and no profound bradycardia or suspected sinus or atrioventricular (AV) node dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148734</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Amiodarone or dronedarone in selected patients who have no other risk factors for torsades de pointes (eg, hypokalemia, hypomagnesemia) or sinus node dysfunction or AV conduction disease.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148735</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Dronedarone and amiodarone are the only two drugs that can be initiated in outpatients while in atrial fibrillation.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="Dronedarone"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148736</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Patients with an implantable cardioverter-defibrillator (ICD) represent another group in which outpatient initiation of therapy can be tried, since the ICD provides protection against the risks associated with bradyarrhythmias and tachyarrhythmias.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148738</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>The initiation of antiarrhythmic drugs in patients with paroxysmal AF while they are in sinus rhythm is also associated with some risk.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H425527372"/>
			<id>148741</id>
			<summary>
				<section label="INPATIENT VERSUS OUTPATIENT INITIATION" id="425527372">
					<fragment>Inpatient initiation with continuous telemetry of higher-risk drugs such as dofetilide and sotalol is typically done over a course of three days, which encompasses five half-lives allowing for achievement of steady-state plasma concentrations.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148743</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>Some patients will elect to continue drug therapy (and, in some cases, occasional cardioversion) because the arrhythmia burden has been substantially reduced as evidenced by episodes that are less frequent, shorter, or associated with milder symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148744</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>Nonpharmacologic therapies are another option in such patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H577202428"/>
			<id>148745</id>
			<summary>
				<section label="AF recurrence" id="577202428">
					<fragment>If a patient has unacceptable recurrent AF on one antiarrhythmic drug, the drug is discontinued and another (and on rare occasion a third) agent is tried.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855015"/>
			<id>148752</id>
			<summary>
				<section label="related arrhythmias and mortality" id="523855015">
					<fragment>Compared to controls, the use of the class IA antiarrhythmics quinidine and disopyramide (odds ratio 2.39, 95% CI 1.03-5.59) or sotalol (2.47, 95% CI 1.2-5.05) was associated with increased all-cause mortality, whereas the use of amiodarone, dronedarone, and dofetilide was not (odds ratios were not calculated for flecainide or propafenone).</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmics"/>
			<category term="C0012702" scheme="gov.nih.nlm.semanticType.phsu" label="disopyramide"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148754</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>All of the antiarrhythmic drugs used to maintain sinus rhythm have the potential to increase ectopy or induce or aggravate monomorphic ventricular tachycardia (VT), torsades de pointes, or ventricular fibrillation (VF);</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148756</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>In addition to its baseline potential to predispose the patient to proarrhythmia, a drug that is initially safe may become proarrhythmic when the patient develops coronary heart disease or heart failure or is treated with other medications that in combination may be arrhythmogenic.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148757</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>Thus, the patient should be alerted to the potential significance of symptoms such as syncope and dyspnea and warned about the use of noncardiac drugs that can prolong the QT interval.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148761</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>For type IA or type III drugs, with the possible exception of amiodarone, the corrected QT interval in sinus rhythm should remain below 520 milliseconds.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148763</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>During follow-up, serum creatinine, potassium, and magnesium concentrations should be monitored periodically because proarrhythmia is increased by renal insufficiency, which can lead to drug accumulation, hyperkalemia, and hypermagnesemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855022"/>
			<id>148765</id>
			<summary>
				<section label="Proarrhythmia" id="523855022">
					<fragment>In comparison, amiodarone is metabolized in the liver and dose adjustment is probably necessary in patients with hepatic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855029"/>
			<id>148766</id>
			<summary>
				<section label="Bradyarrhythmia" id="523855029">
					<fragment>Amiodarone and dronedarone can cause both sinus bradycardia and AV nodal block, with an overall incidence of bradycardic events of about 5 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523855029"/>
			<id>148767</id>
			<summary>
				<section label="Bradyarrhythmia" id="523855029">
					<fragment>Sotalol, like other beta blockers, can also cause bradycardia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="Sotalol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H266072426"/>
			<id>148777</id>
			<summary>
				<section label="term therapy" id="266072426">
					<fragment>This concept was tested in the Flec-SL non-inferiority trial, which randomly assigned 554 patients with persistent AF and who were intended to undergo cardioversion to either four weeks or six months of flecainide (200 to 300 mg per day).</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0044225" scheme="gov.nih.nlm.semanticType.phsu" label="Flec"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308714" scheme="gov.nih.nlm.semanticType.phsu" label="concept"/>
			<category term="C1569181" scheme="gov.nih.nlm.semanticType.aapp" label="SL"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148782</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>Patients with severe heart failure (HF) (generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks) or those with an ejection fraction of &lt;35 percent should not receive dronedarone.</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148783</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The Permanent Atrial fibriLLAtion outcome Study (PALLAS) was designed to test the hypothesis that dronedarone would improve major outcomes in 10,000 patients with permanent AF, over 70 percent of whom had New York Heart Association heart failure class I to III or left ventricular systolic dysfunction at baseline.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148787</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The study was stopped early (3236 patients enrolled), after a significantly increased risk (Hazard Ratio 2.29, 95% CI 1.34-3.94) of cardiovascular events (cardiovascular death, myocardial infarction, stroke and systemic embolism) was observed in the dronedarone arm.</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148788</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>The individual secondary end points of stroke, death from cardiovascular causes, and hospitalization for heart failure were also significantly increased in the dronedarone group.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148790</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>In addition, the USFDA now recommends that people taking the drug should have an electrocardiogram every three months to make sure that AF has not become permanent.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H58992353"/>
			<id>148791</id>
			<summary>
				<section label="Concerns about dronedarone" id="58992353">
					<fragment>For patients taking dronedarone, routine monitoring of lung and liver function is not mandated by the USFDA;</fragment>
				</section>
			</summary>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148793</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>Our recommendations for the use of antiarrhythmic drugs to maintain sinus rhythm in patients with AF are generally in agreement with the American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines on AF and the 2010 European Society of Cardiology guidelines on AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148794</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>The 2006 American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend propafenone, flecainide, and sotalol as first-line drugs to maintain sinus rhythm after cardioversion in patients without structural heart disease;</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148795</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>amiodarone and dofetilide can also be given as second-line agents.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148797</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>These drugs are generally better tolerated and perhaps safer than the class IA drugs, such as quinidine, which were widely used in the past.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H523850780"/>
			<id>148798</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="523850780">
					<fragment>Because of concerns about toxicity, the ACC/AHA/ESC guidelines recommend that the use of amiodarone as a first-line therapy for maintenance of sinus rhythm should be reserved for patients with heart failure, moderate-to-severe systolic dysfunction, or hypertension with substantial left ventricular hypertrophy.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148808</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For those patients with atrial fibrillation (AF) in whom a rhythm-control strategy is chosen, the principal goal is to reduce symptoms by decreasing the frequency and duration of episodes.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148810</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>The following points should be kept in mind when considering antiarrhythmic drug therapy to maintain sinus rhythm in patients with AF: Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148811</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Compared to placebo, amiodarone, sotalol, dofetilide, dronedarone, flecainide, and propafenone are effective for the maintenance of sinus rhythm, but maintenance rates at one year are significantly less than 75 percent.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148812</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Amiodarone is consistently more effective than the other antiarrhythmic drugs.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148815</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Although a drug may be shown to significantly prolong the time to recurrence of AF in a clinical trial, individual patients may experience no benefit or experience a dramatic reduction in AF frequency.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148822</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>We make the following recommendations for the choice of antiarrhythmic drug to maintain sinus rhythm in patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148823</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with no structural heart disease and no apparent risk for drug-induced bradycardia or tachycardia, we suggest flecainide as the preferred antiarrhythmic drug.</fragment>
				</section>
			</summary>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148826</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with coronary artery disease who do not have advanced heart failure, we suggest dronedarone or sotalol in preference to amiodarone.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148827</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Amiodarone is a reasonable choice in patients who prefer its greater efficacy despite its worse extracardiac side-effect profile.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148828</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with heart failure, we suggest amiodarone in preference to dofetilide.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0114771" scheme="gov.nih.nlm.semanticType.phsu" label="dofetilide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148829</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>Flecainide, propafenone, dronedarone, and sotalol are contraindicated in these patients.</fragment>
				</section>
			</summary>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="Flecainide"/>
			<category term="C0033429" scheme="gov.nih.nlm.semanticType.phsu" label="propafenone"/>
			<category term="C0037707" scheme="gov.nih.nlm.semanticType.phsu" label="sotalol"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1035#H5304343"/>
			<id>148830</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="5304343">
					<fragment>For patients with left ventricular hypertrophy, either amiodarone or dronedarone is generally preferred to other antiarrhythmic agents.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0003195" scheme="gov.nih.nlm.semanticType.phsu" label="antiarrhythmic"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Control of ventricular rate in atrial fibrillation: Pharmacologic therapy</title>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="met"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C1627358" scheme="gov.nih.nlm.semanticType.topp" label="Enhancement"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="Esmolol"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="esmolol"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0022860" scheme="gov.nih.nlm.semanticType.phsu" label="labetalol"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="Carvedilol"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="Calcium channel blockers"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1258377" scheme="gov.nih.nlm.semanticType.orch" label="SA"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C1258377" scheme="gov.nih.nlm.semanticType.orch" label="SA"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="Verapamil"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0004147" scheme="gov.nih.nlm.semanticType.phsu" label="atenolol"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C3177975" scheme="gov.nih.nlm.semanticType.phsu" label="CD"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0004147" scheme="gov.nih.nlm.semanticType.phsu" label="atenolol"/>
		<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
		<category term="C0027302" scheme="gov.nih.nlm.semanticType.phsu" label="nadolol"/>
		<category term="C0031937" scheme="gov.nih.nlm.semanticType.phsu" label="pindolol"/>
		<category term="C0040233" scheme="gov.nih.nlm.semanticType.phsu" label="timolol"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0022860" scheme="gov.nih.nlm.semanticType.phsu" label="labetalol"/>
		<category term="C0055021" scheme="gov.nih.nlm.semanticType.phsu" label="celiprolol"/>
		<category term="C0078595" scheme="gov.nih.nlm.semanticType.phsu" label="xamoterol"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
		<category term="C0033497" scheme="gov.nih.nlm.semanticType.phsu" label="propranolol"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="esmolol"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<id>938</id>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H2"/>
			<id>214092</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="2">
					<fragment>The initial management of patients with atrial fibrillation (AF) and a rapid ventricular response involves two decisions: Determining the urgency of initial therapy (eg, intravenous versus oral rate control therapy, and/or immediate versus elective cardioversion).</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H2"/>
			<id>214095</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="2">
					<fragment>As an example, a patient for whom rate control may be the appropriate long-term strategy may require urgent cardioversion in the acute setting due to hemodynamic instability.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H2"/>
			<id>214098</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="2">
					<fragment>Selection of an appropriate regimen is guided by an understanding of the determinants of the ventricular rate in AF and a structured method for assessing the adequacy of rate control.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H3"/>
			<id>214102</id>
			<summary>
				<section label="Determinants of ventricular rate" id="3">
					<fragment>In most myocardial tissue, the initial depolarizing phase of the action potential (phase 0) is mediated by rapid sodium channels.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H3"/>
			<id>214103</id>
			<summary>
				<section label="Determinants of ventricular rate" id="3">
					<fragment>In contrast, in the slow response fibers of the AV node, phase 0 is mediated by an inward calcium current, which uses a kinetically slow channel.</fragment>
				</section>
			</summary>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214116</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>Achieving rates similar to those recommended for patients in sinus rhythm with heart disease has been advocated: resting heart rate &lt;=80 beats/min and &lt;=110 beats/min during moderate exercise such as with the six-minute walk.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214118</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>This issue was directly addressed in the RACE II trial, which randomly assigned 614 physically active patients with permanent AF to either a lenient rate control strategy (resting heart rate &lt;110 beats per minute) or a strict rate control strategy (resting heart rate &lt;80 beats per minute and heart rate during moderate exercise &lt;110 beats per minute).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214119</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>The primary outcome was a composite of cardiovascular death, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214123</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>When the data were analyzed from the end of the dose-adjustment phase until the end of follow-up (median 2.9 years), the average heart rates in the lenient control group, strict control group patients who met the target, and strict control group patients who failed to meet the target were significantly different at 93, 72, and 86 beats per minute, respectively.</fragment>
				</section>
			</summary>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="met"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214128</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>By comparison, mean resting rates in the strict control group were 75+12, 75+12, and 76+14 beats per minute, respectively.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214129</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>Based upon the results of the RACE II trial, we believe that achieving strict heart rate control is not necessary in many physically active patients with AF who are minimally symptomatic.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H4"/>
			<id>214132</id>
			<summary>
				<section label="Rate control goals" id="4">
					<fragment>It is important to consider that symptoms may be due to either inadequate rate control or relative bradycardia (eg, in patients with tachy-brady syndrome).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H537237617"/>
			<id>214138</id>
			<summary>
				<section label="mediated cardiomyopathy" id="537237617">
					<fragment>Persistently increased ventricular rates in AF have been associated with a left ventricular cardiomyopathy.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H537237617"/>
			<id>214140</id>
			<summary>
				<section label="mediated cardiomyopathy" id="537237617">
					<fragment>Some experts perform an echocardiogram every two to three years in asymptomatic patients with higher average ventricular rates while others do not.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H6"/>
			<id>214141</id>
			<summary>
				<section label="Urgency of therapy" id="6">
					<fragment>In a patient with new or recurrent AF with a rapid ventricular response, the intensity of initial therapy depends upon the clinical scenario: Emergent therapy - In patients who are clinically or hemodynamically unstable (eg, myocardial ischemia, pulmonary edema, hypotension) due to AF and a rapid ventricular response, treatment options include intravenous rate control medications and/or immediate cardioversion ).</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H6"/>
			<id>214142</id>
			<summary>
				<section label="Urgency of therapy" id="6">
					<fragment>In patients with an adequate blood pressure, pharmacologic rate control with intravenous calcium channel blockers or beta blockers may be attempted, while arrangements are made for cardioversion.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H6"/>
			<id>214143</id>
			<summary>
				<section label="Urgency of therapy" id="6">
					<fragment>If the patient responds to rate control therapy but remains unstable, an explanation other than AF with a rapid ventricular response should be sought.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H6"/>
			<id>214145</id>
			<summary>
				<section label="Urgency of therapy" id="6">
					<fragment>Patients who are chronically managed with a rhythm control strategy can undergo cardioversion if they have been adequately anticoagulated or are considered to have a low thromboembolic risk.</fragment>
				</section>
			</summary>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H7"/>
			<id>214147</id>
			<summary>
				<section label="Rhythm versus rate control" id="7">
					<fragment>The two main therapeutic strategies in patients with AF are: Rhythm control, which consists of cardioversion, often followed by maintenance of sinus rhythm with arrhythmic drugs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0013778" scheme="gov.nih.nlm.semanticType.topp" label="cardioversion"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H7"/>
			<id>214149</id>
			<summary>
				<section label="Rhythm versus rate control" id="7">
					<fragment>In the past, many physicians preferred a rhythm control strategy because of presumed improvements in symptoms, hemodynamics, and embolic risk.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H7"/>
			<id>214151</id>
			<summary>
				<section label="Rhythm versus rate control" id="7">
					<fragment>As a result, a rate control strategy is now preferred in most asymptomatic patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H9"/>
			<id>214159</id>
			<summary>
				<section label="PHARMACOLOGIC TREATMENT" id="9">
					<fragment>These agents slow atrioventricular (AV) nodal conduction based upon the following physiologic mechanisms: Blockade of the calcium channel with the nondihydropyridine calcium channel blockers verapamil and diltiazem.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H9"/>
			<id>214161</id>
			<summary>
				<section label="PHARMACOLOGIC TREATMENT" id="9">
					<fragment>Enhancement of parasympathetic tone with vagotonic drugs, the most important of which is digoxin.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C1627358" scheme="gov.nih.nlm.semanticType.topp" label="Enhancement"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H10"/>
			<id>214162</id>
			<summary>
				<section label="Beta blockers" id="10">
					<fragment>Beta blockers are commonly used for both the acute and chronic control of ventricular rates in patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H11"/>
			<id>214168</id>
			<summary>
				<section label="Acute control with beta blockers" id="11">
					<fragment>Esmolol is a rapidly acting intravenous beta blocker that is metabolized by red blood cell esterase, resulting in a short duration of action (10 to 20 minutes).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="Esmolol"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H11"/>
			<id>214171</id>
			<summary>
				<section label="Acute control with beta blockers" id="11">
					<fragment>The following esmolol regimen is recommended for acute rate control: A bolus of 0.5 mg/kg is infused over one minute, followed by 50 microg/kg per min.</fragment>
				</section>
			</summary>
			<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="esmolol"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214179</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>There are some data that labetalol is less effective than other beta blockers for reducing heart rate at rest.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0022860" scheme="gov.nih.nlm.semanticType.phsu" label="labetalol"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214184</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>Beta blockers have additional properties that may make them preferred to other rate control drugs in some AF patients: Patients with chronic heart failure due to systolic dysfunction - A retrospective analysis from the United States Carvedilol Trials Program evaluated 1094 heart failure patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="Carvedilol"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214186</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>In addition, there was a trend toward a decrease in the combined end point of death or hospitalization for heart failure.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214187</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>Beta blockers may reduce the incidence of AF recurrence in patients with episodes of AF that are triggered by surges in sympathetic activity.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214189</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>Some of these complications that may be important in patients with AF include: Worsening heart failure.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H12"/>
			<id>214195</id>
			<summary>
				<section label="Chronic beta blocker therapy" id="12">
					<fragment>Some patients with paroxysmal AF also have sinus node dysfunction, with the tachycardia-bradycardia syndrome.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H13"/>
			<id>214197</id>
			<summary>
				<section label="Calcium channel blockers" id="13">
					<fragment>The nondihydropyridine calcium channel blockers verapamil and diltiazem are useful in the management of AF in the absence of preexcitation.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214225</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>Calcium channel blockers have a number of characteristics that need to be considered when they are administered to patients with AF: The effect on sinoatrial (SA) nodal function is variable.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="Calcium channel blockers"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1258377" scheme="gov.nih.nlm.semanticType.orch" label="SA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214226</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>Although both verapamil and diltiazem have an inhibitory effect on the sinus node, their vasodilator effects cause a reflex release of catecholamines that usually maintains or slightly accelerates the SA nodal rate.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C1258377" scheme="gov.nih.nlm.semanticType.orch" label="SA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214227</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>However, patients with the sick sinus syndrome may be particularly sensitive to the effects of calcium channel blockers.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214229</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>As a result, these drugs should be used with caution in patients with heart failure and in patients taking other negative inotropes, such as beta blockers.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214231</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>Verapamil interacts with digoxin, resulting in an increase in serum digoxin.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="Verapamil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214233</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>Similar to the digoxin-quinidine interaction, verapamil reduces the renal clearance of digoxin;</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H16"/>
			<id>214237</id>
			<summary>
				<section label="Clinical cautions" id="16">
					<fragment>In summary, diltiazem and verapamil should not be given to patients with severe heart failure (New York Heart Failure class III or IV), the preexcitation syndrome, or significant hypotension.</fragment>
				</section>
			</summary>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H17"/>
			<id>214239</id>
			<summary>
				<section label="Digoxin" id="17">
					<fragment>Digoxin slows the ventricular rate during AF primarily by vagotonic inhibition of AV nodal conduction.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H17"/>
			<id>214240</id>
			<summary>
				<section label="Digoxin" id="17">
					<fragment>Digoxin is generally less effective for rate control than beta blockers or calcium channel blockers, particularly during exercise when vagal tone is low and sympathetic tone is high.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H17"/>
			<id>214241</id>
			<summary>
				<section label="Digoxin" id="17">
					<fragment>For these reasons, digoxin should not be used as a first-line drug for rate control in most settings.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H18"/>
			<id>214242</id>
			<summary>
				<section label="Left ventricular dysfunction" id="18">
					<fragment>In patients with heart failure due to systolic dysfunction and AF, digoxin has two potential benefits: reduction in the ventricular rate and improvement in contractility.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H18"/>
			<id>214244</id>
			<summary>
				<section label="Left ventricular dysfunction" id="18">
					<fragment>However, beta blockers, if tolerated, are now a standard component of therapy for all patients with heart failure due to systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H18"/>
			<id>214245</id>
			<summary>
				<section label="Left ventricular dysfunction" id="18">
					<fragment>Thus, in patients with left ventricular dysfunction, the use of digoxin is limited to the following settings: Patients who do not achieve rate control targets on beta blockers alone.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H18"/>
			<id>214247</id>
			<summary>
				<section label="Left ventricular dysfunction" id="18">
					<fragment>Patients in whom digoxin would be added for improved control of heart failure symptoms independent of AF.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H18"/>
			<id>214248</id>
			<summary>
				<section label="Left ventricular dysfunction" id="18">
					<fragment>Many such patients will already be treated with a beta blocker, and care must be taken to avoid excessive bradycardia.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H20"/>
			<id>214257</id>
			<summary>
				<section label="Amiodarone" id="20">
					<fragment>Amiodarone is commonly used to maintain sinus rhythm in AF patients in whom a rhythm control strategy is chosen.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="Amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H20"/>
			<id>214258</id>
			<summary>
				<section label="Amiodarone" id="20">
					<fragment>However, amiodarone can also slow the ventricular rate in patients who remain in AF.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H20"/>
			<id>214259</id>
			<summary>
				<section label="Amiodarone" id="20">
					<fragment>In one study, for example, intravenous amiodarone (7 mg/kg), flecainide, or placebo was given to 98 patients with recent onset AF (0.5 to 72 hours).</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="C0016229" scheme="gov.nih.nlm.semanticType.phsu" label="flecainide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H20"/>
			<id>214261</id>
			<summary>
				<section label="Amiodarone" id="20">
					<fragment>In addition, in critically ill patients, amiodarone may be less likely to cause systemic hypotension than intravenous diltiazem.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H20"/>
			<id>214263</id>
			<summary>
				<section label="Amiodarone" id="20">
					<fragment>We agree with this assessment and recommend that patients treated with amiodarone receive careful follow-up, including monitoring for know side effects.</fragment>
				</section>
			</summary>
			<category term="C0002598" scheme="gov.nih.nlm.semanticType.phsu" label="amiodarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H22"/>
			<id>214273</id>
			<summary>
				<section label="COMPARATIVE EFFICACY" id="22">
					<fragment>Thus, it is particularly important to assess heart rate with exertion in patients treated with digoxin alone.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H22"/>
			<id>214274</id>
			<summary>
				<section label="COMPARATIVE EFFICACY" id="22">
					<fragment>In a small crossover study of 12 patients with chronic AF, patients were treated for two-week intervals with five different drug regimens: digoxin 0.25 mg daily, diltiazem-CD 240 mg daily, atenolol 50 mg daily, digoxin plus diltiazem, and digoxin plus atenolol.</fragment>
				</section>
			</summary>
			<category term="C0004147" scheme="gov.nih.nlm.semanticType.phsu" label="atenolol"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C3177975" scheme="gov.nih.nlm.semanticType.phsu" label="CD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H23"/>
			<id>214289</id>
			<summary>
				<section label="AFFIRM trial" id="23">
					<fragment>Patients initially treated with a beta blocker were significantly less likely than those treated with calcium channel blockers or digoxin to have their drug regimen changed.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H23"/>
			<id>214292</id>
			<summary>
				<section label="AFFIRM trial" id="23">
					<fragment>beta blockers were more commonly used in patients with coronary disease, calcium channel blockers were more often given to patients with pulmonary disease and to women, while digoxin was used more often in patients with cardiomyopathy and in nonwhite patients.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="11" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H23"/>
			<id>214294</id>
			<summary>
				<section label="AFFIRM trial" id="23">
					<fragment>Only 361 (18 percent) of the patients assigned to the rate control strategy had an initial assessment of the adequacy of rate control at rest and with exertion.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H23"/>
			<id>214295</id>
			<summary>
				<section label="AFFIRM trial" id="23">
					<fragment>This is because many patients spontaneously reverted to sinus rhythm (and therefore, rate control could not be assessed), and also because of the limited number of patients in atrial fibrillation (AF) who had heart rate assessed with exertion.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H24"/>
			<id>214300</id>
			<summary>
				<section label="Systematic review" id="24">
					<fragment>However, the following observations were noted: Diltiazem, verapamil, and most beta blockers (atenolol, metoprolol, timolol, pindolol, and nadolol) were all effective in reducing the ventricular rate during rest and exercise.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0004147" scheme="gov.nih.nlm.semanticType.phsu" label="atenolol"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0027302" scheme="gov.nih.nlm.semanticType.phsu" label="nadolol"/>
			<category term="C0031937" scheme="gov.nih.nlm.semanticType.phsu" label="pindolol"/>
			<category term="C0040233" scheme="gov.nih.nlm.semanticType.phsu" label="timolol"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H24"/>
			<id>214301</id>
			<summary>
				<section label="Systematic review" id="24">
					<fragment>The beta blockers labetalol, xamoterol, and celiprolol were less effective at rest, but did reduce ventricular rates during exercise.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0022860" scheme="gov.nih.nlm.semanticType.phsu" label="labetalol"/>
			<category term="C0055021" scheme="gov.nih.nlm.semanticType.phsu" label="celiprolol"/>
			<category term="C0078595" scheme="gov.nih.nlm.semanticType.phsu" label="xamoterol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H24"/>
			<id>214303</id>
			<summary>
				<section label="Systematic review" id="24">
					<fragment>The combination of digoxin with a beta blocker or calcium channel blocker reduced heart rate both at rest and with exertion.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H26"/>
			<id>214317</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="26">
					<fragment>The following summary and recommendations are in general agreement with the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines on atrial fibrillation (AF) . This discussion applies to AF patients in whom a chronic rate control strategy has been chosen, or to any AF patient requiring acute rate control.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H27"/>
			<id>214320</id>
			<summary>
				<section label="Acute rate control" id="27">
					<fragment>In such patients, we suggest the following approach: In patients without significant heart failure or hypotension, we suggest intravenous beta blockers or nondihydropyridine calcium channel blockers . Intravenous diltiazem, using the regimen described above, is our preferred drug in this setting.verapamil or intravenous beta blockers such as metoprolol, propranolol, or esmolol are reasonable alternatives.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0033497" scheme="gov.nih.nlm.semanticType.phsu" label="propranolol"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0116569" scheme="gov.nih.nlm.semanticType.phsu" label="esmolol"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H27"/>
			<id>214324</id>
			<summary>
				<section label="Acute rate control" id="27">
					<fragment>However, in selected patients who do not have hypotension or significant left ventricular dysfunction, these classes may be used together, and in some cases all three agents (ie, a beta blocker, a calcium channel blocker, and digoxin) may be necessary to achieve adequate rate control.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214332</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>For patients who continue with unacceptable symptoms at this goal, an attempt should be made to see if a lower goal lessens symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214334</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>Beta blockers are preferred in patients with coronary heart disease, heart failure due to systolic dysfunction, and in patients in whom the ventricular rate increases inappropriately during exercise.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214335</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>In the first two settings, beta blockers improve patient survival.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214336</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>Despite these advantages, beta blockers are contraindicated or relatively contraindicated in some patients, and others cannot tolerate the side effects.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214337</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>A nondihydropyridine calcium channel blocker is preferred in patients with chronic lung disease and in patients who do not tolerate a beta blocker.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214338</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>Among the calcium channel blockers, verapamil has a somewhat greater blocking effect on the AV node than diltiazem, and the choice between these drugs is often dictated by side effects.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C2934036" scheme="gov.nih.nlm.semanticType.orch" label="AV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H28"/>
			<id>214339</id>
			<summary>
				<section label="Chronic rate control" id="28">
					<fragment>Diltiazem may be preferred in patients with mild heart failure if a beta blocker is contraindicated or not tolerated.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/938#H29"/>
			<id>214345</id>
			<summary>
				<section label="Combination therapy" id="29">
					<fragment>Although some patients may not tolerate both a beta blocker and a calcium channel blocker (eg, those with left ventricular systolic dysfunction or hypotension), the combination can be tried in most patients.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Antithrombotic therapy to prevent embolization in atrial fibrillation</title>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0019120" scheme="gov.nih.nlm.semanticType.phsu" label="hemostatic"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0178906" scheme="gov.nih.nlm.semanticType.hlca" label="quality monitoring"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0249610" scheme="gov.nih.nlm.semanticType.phsu" label="OAC"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0104653" scheme="gov.nih.nlm.semanticType.phsu" label="ATRIA"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevented"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0249610" scheme="gov.nih.nlm.semanticType.phsu" label="OAC"/>
		<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
		<category term="C2825026" scheme="gov.nih.nlm.semanticType.phsu" label="unfractionated heparin"/>
		<category term="C3536766" scheme="gov.nih.nlm.semanticType.phsu" label="low-molecular-weight heparin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
		<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
		<category term="C0522794" scheme="gov.nih.nlm.semanticType.topp" label="heparin therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1277289" scheme="gov.nih.nlm.semanticType.topp" label="stroke prevention"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonists"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C1532338" scheme="gov.nih.nlm.semanticType.topp" label="percutaneous coronary intervention"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
		<category term="C2975435" scheme="gov.nih.nlm.semanticType.phsu" label="edoxaban"/>
		<category term="C0003295" scheme="gov.nih.nlm.semanticType.phsu" label="antidote"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2975435" scheme="gov.nih.nlm.semanticType.phsu" label="edoxaban"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0206460" scheme="gov.nih.nlm.semanticType.phsu" label="enoxaparin"/>
		<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
		<category term="C0003295" scheme="gov.nih.nlm.semanticType.phsu" label="antidote"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0185027" scheme="gov.nih.nlm.semanticType.topp" label="overlap"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="Aspirin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
		<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0966370" scheme="gov.nih.nlm.semanticType.phsu" label="ximelagatran"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agent"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0162561" scheme="gov.nih.nlm.semanticType.topp" label="radiofrequency catheter ablation"/>
		<category term="C0162563" scheme="gov.nih.nlm.semanticType.topp" label="catheter ablation"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0547070" scheme="gov.nih.nlm.semanticType.topp" label="ablation"/>
		<category term="C2587206" scheme="gov.nih.nlm.semanticType.topp" label="maze procedure"/>
		<category term="C3544330" scheme="gov.nih.nlm.semanticType.topp" label="pulmonary vein isolation"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="Combined therapy"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agents"/>
		<category term="C1620287" scheme="gov.nih.nlm.semanticType.phsu" label="prasugrel"/>
		<category term="C1999375" scheme="gov.nih.nlm.semanticType.phsu" label="ticagrelor"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C1704311" scheme="gov.nih.nlm.semanticType.phsu" label="antithrombotic agents"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C1704311" scheme="gov.nih.nlm.semanticType.phsu" label="antithrombotic agents"/>
		<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agent"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="Aspirin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
		<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
		<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
		<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="Rivaroxaban"/>
		<id>1031</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H2"/>
			<id>205898</id>
			<summary>
				<section label="PATIENTS WITH VALVULAR HEART DISEASE" id="2">
					<fragment>Many, but not all, of the major clinical trials of antithrombotic therapy and subsequent meta-analyses have excluded patients with any type of prosthetic heart valves, those with mitral stenosis, and those with decompensated valvular heart disease who were likely to require valve replacement in the near future.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H2"/>
			<id>205899</id>
			<summary>
				<section label="PATIENTS WITH VALVULAR HEART DISEASE" id="2">
					<fragment>Based on these studies, the newer anticoagulants should not be prescribed for these patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H2"/>
			<id>205901</id>
			<summary>
				<section label="PATIENTS WITH VALVULAR HEART DISEASE" id="2">
					<fragment>Some patients with valvular lesions (without heart failure) such as mitral valve prolapse, non-rheumatic mitral regurgitation, or aortic valve lesions have been enrolled in the clinical trials of the newer anticoagulants.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H2"/>
			<id>205902</id>
			<summary>
				<section label="PATIENTS WITH VALVULAR HEART DISEASE" id="2">
					<fragment>These trials also likely included a few patients (with or without heart failure) with severe valvular lesions who were not scheduled to undergo valve replacement.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H2"/>
			<id>205903</id>
			<summary>
				<section label="PATIENTS WITH VALVULAR HEART DISEASE" id="2">
					<fragment>Until further evidence is available, we believe these newer drugs can be considered for these patients.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621955964"/>
			<id>205904</id>
			<summary>
				<section label="MECHANISM OF THROMBOEMBOLISM" id="621955964">
					<fragment>The mechanisms leading to an increased risk of thrombus, embolism, and stroke in atrial fibrillation (AF) are multiple and closely interact with each other.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621955964"/>
			<id>205905</id>
			<summary>
				<section label="MECHANISM OF THROMBOEMBOLISM" id="621955964">
					<fragment>Blood stasis, especially in the left atrial appendage (LAA), and activation of the hemostatic system are thought to play primary roles in patients with nonvalvular AF.</fragment>
				</section>
			</summary>
			<category term="C0019120" scheme="gov.nih.nlm.semanticType.phsu" label="hemostatic"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H3"/>
			<id>205908</id>
			<summary>
				<section label="RISK STRATIFICATION TO GUIDE THERAPY" id="3">
					<fragment>Many studies have evaluated risk factors for embolization in nonvalvular atrial fibrillation (AF), and multivariate risk models have been constructed.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H3"/>
			<id>205913</id>
			<summary>
				<section label="RISK STRATIFICATION TO GUIDE THERAPY" id="3">
					<fragment>Use of the CHA2DS2-VASc model will lead a recommendation for antithrombotic therapy in a higher percent of AF patients, including all of those for whom the recommendation would be for anticoagulation using CHADS2 alone.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H5"/>
			<id>205919</id>
			<summary>
				<section label="ANTITHROMBOTIC PREVENTION" id="5">
					<fragment>These trials and meta-analyses have demonstrated that among patients with AF at moderate to high risk of thromboembolic events, warfarin, compared to placebo, significantly reduces the incidence of clinical stroke at an acceptable risk of bleeding.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H5"/>
			<id>205921</id>
			<summary>
				<section label="ANTITHROMBOTIC PREVENTION" id="5">
					<fragment>The vitamin K antagonist warfarin is approximately three times as effective as aspirin.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H5"/>
			<id>205922</id>
			<summary>
				<section label="ANTITHROMBOTIC PREVENTION" id="5">
					<fragment>The benefit to risk ratio from oral anticoagulation in patients at low risk, such as those with a CHADS2 score of 0 or a CHA2DS2-VASc score of 1, has not been well studied.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H5"/>
			<id>205923</id>
			<summary>
				<section label="ANTITHROMBOTIC PREVENTION" id="5">
					<fragment>If the use of antithrombotic therapy carried no risk or cost, virtually all patients with AF would receive such preventative therapy.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205927</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Long-term antithrombotic therapy, usually with anticoagulant therapy, is recommended for most patients with AF who have CHADS-2 risk factors for stroke.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205931</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Patients with a CHADS2 score of 0 who receive no antithrombotic therapy are at low risk of stroke (rate of 0.5 to 1.7 percent per year), and a benefit from aspirin has not been conclusively shown in these patients.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205933</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Patients with a CHADS2 score of 1 are at intermediate risk of stroke (2.0 percent per year, or perhaps somewhat less) and should be treated with oral anticoagulant therapy or aspirin (75 to 325 mg daily).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205934</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Based on the studies discussed below, which show that anticoagulant is more effective than aspirin, we prefer anticoagulant therapy to aspirin in most CHADS2 patients with a score of 1, especially for patients more fearful of stroke as compared with bleeding.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205935</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>The choice between anticoagulation and aspirin will depend upon many factors, including the clinician's assessment of risk, the ability to provide high-quality monitoring of the intensity of oral anticoagulation (if warfarin is chosen as the anticoagulant) and regimen compliance, the patient's risk of bleeding with oral anticoagulation, and patient preference (including issues related to cost, convenience of monitoring, and dose frequency).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0178906" scheme="gov.nih.nlm.semanticType.hlca" label="quality monitoring"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205936</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Patient preference is an important issue, since the absolute reduction in stroke risk is likely to be small, but stroke remains a feared outcome.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205938</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>The role of dual antiplatelet therapy with aspirin plus clopidogrel remains unclear in patients with a CHADS2 score of 1 who do not wish to take anticoagulant therapy, for reasons such as the inconvenience of INR monitoring or cost of the newer agents.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205941</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>As antiplatelet therapy is inferior to anticoagulant therapy with regard to efficacy, patients should be fully informed of this fact before a decision is made to choose antiplatelet therapy.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205942</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>If the reason for not choosing anticoagulant therapy is concern about bleeding, aspirin plus clopidogrel is not beneficial, as the combination produces a similar risk of bleeding to that seen with warfarin.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205944</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Thus, oral anticoagulant therapy is strongly recommended for most patients with a CHADS2 score of 2 or higher.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956305"/>
			<id>205950</id>
			<summary>
				<section label="Prevention approach by CHADS2 score" id="621956305">
					<fragment>Patients with chronic severe kidney disease, whose estimated creatinine clearance is less than 30 mL/min.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956777"/>
			<id>205951</id>
			<summary>
				<section label="VASc score" id="621956777">
					<fragment>Some of our authors and reviewers, who support the use of the CHA2DS2-VASc score, consider it reasonable to choose antithrombotic therapy for patients with none of the CHADS2 but one of the additional CHA2DS2-VASc risk factors: age 65 to 74 years, female sex, and evidence of atherosclerotic cardiovascular disease.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H621956777"/>
			<id>205952</id>
			<summary>
				<section label="VASc score" id="621956777">
					<fragment>Benefit from therapy in such patients has not been established in randomized trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H1127350851"/>
			<id>205959</id>
			<summary>
				<section label="Patients with chronic kidney disease" id="1127350851">
					<fragment>While not included in the CHADS2 or CHA2DS2-VASc risk prediction models, chronic kidney disease (estimated creatinine clearance is less than 60 mL/min) is a powerful predictor of thromboembolic risk in patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H147982501"/>
			<id>205961</id>
			<summary>
				<section label="Studies of anticoagulant monotherapy" id="147982501">
					<fragment>In large randomized trials of patients at intermediate and high risk for clinical thromboembolism, warfarin has been compared to placebo and to the newer oral anticoagulants (dabigatran, rivaroxaban, and apixaban).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H147982501"/>
			<id>205965</id>
			<summary>
				<section label="Studies of anticoagulant monotherapy" id="147982501">
					<fragment>These newer oral anticoagulants (compared to warfarin) are associated with the following: A significant reduction of stroke/systemic embolism (odds ratio [OR] 0.85, 95% CI 0.74-0.99;</fragment>
				</section>
			</summary>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205971</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>Together, these trials randomly assigned more than 4000 patients with nonvalvular or nonrheumatic AF to aspirin, warfarin, or placebo, and demonstrated that anticoagulation with adjusted-dose warfarin (equivalent to INR 2 to 3) significantly reduced clinical stroke risk in patients with AF when compared with aspirin or placebo.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205972</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>Overall, adjusted-dose warfarin reduces the risk of stroke by two-thirds compared to no antithrombotic therapy, with the expected degree of absolute benefit dependent on baseline risk.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205974</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>Warfarin was effective in both men and women and in all age groups, including those over the age of 75 years.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205975</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>In addition, mortality was significantly reduced by warfarin compared to no antithrombotic therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205976</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>In addition, warfarin provides benefit in patients who have already had a stroke.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205979</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>More contemporary data regarding the risk of stroke or systemic embolism in patients treated with warfarin from over 20,000 AF patients are available from the RE-LY, ARISTOTLE, and ROCKET AF trials in which a target INR of 2.0 to 3.0 was universally used for patients with AF randomized to warfarin.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H7"/>
			<id>205981</id>
			<summary>
				<section label="Efficacy" id="7">
					<fragment>A 2012 meta-analysis of eight randomized trials (published between 2003 and 2011), which included nearly 56,000 individuals treated with warfarin, found that the annual incidence of stroke or systemic embolism was 1.66 percent (95% CI 1.41-1.91).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>205991</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>In the individual patient meta-analysis of six prevention trials cited above, the absolute rate increase of major bleeding with warfarin compared with aspirin was 0.9 events per 100 patient-years (2.2 versus 1.3 events per 100 patient-years).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>205993</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>Many patients on warfarin require aspirin for another indication, such as the prevention of intracoronary stent thrombosis or the prevention of recurrent events after an acute coronary syndrome.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>205994</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>The combination of warfarin and aspirin increases the risk of major bleeding and ICH;</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>205997</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>In a meta-analysis of six randomized trials with 3874 patients, combination therapy was associated with a significant increase in the risk of ICH (relative risk 2.4, 95% CI 1.2-4.8).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>205998</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>In the ORBIT-AF registry of patients with AF, 7347 were taking oral anticoagulant (OAC) alone (warfarin in more than 90 percent) and 2543 taking an OAC plus aspirin (81 mg in 89 percent).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0249610" scheme="gov.nih.nlm.semanticType.phsu" label="OAC"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>206000</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>The rates of major bleeding in patients taking the newer oral anticoagulants (ie, dabigatran, rivaroxaban, and apixaban) are presented below and are similar to or less than the rate in patients taking warfarin.</fragment>
				</section>
			</summary>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulants"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H8"/>
			<id>206001</id>
			<summary>
				<section label="Bleeding risk" id="8">
					<fragment>The management of anticoagulant therapy in patients who are bleeding is discussed elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206002</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>The decision to use antithrombotic therapy to prevent clinical embolization in patients with nonvalvular AF is based upon an assessment of the absolute benefits and risks of such therapy.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206005</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>The ATRIA study evaluated the net clinical benefit (NCB) of warfarin in 13,559 patients with nonvalvular AF who were identified in an outpatient database in 1996 and 1997.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0104653" scheme="gov.nih.nlm.semanticType.phsu" label="ATRIA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206006</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>NCB was defined as the difference between annualized rate of thromboembolic events prevented by warfarin, minus the annualized rate of ICH induced by warfarin, multiplied by a weighting factor.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevented"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206007</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>In the model, ICH was weighted as 1.5 times the impact of ischemic stroke.</fragment>
				</section>
			</summary>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206013</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>The NCB with warfarin in patients with a CHADS2 score of 1 was small, and the confidence intervals around the NCB included the possibility of harm.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H9"/>
			<id>206018</id>
			<summary>
				<section label="Net clinical benefit" id="9">
					<fragment>While most patients with risk factors for bleeding have a CHADS2 score greater than 1, some risk factors for bleeding such as history of gastrointestinal bleeding, abnormal renal or hepatic function, drugs or alcohol, or high risk for falls are not included in the CHADS2 model.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206020</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>The choice of whether to start OAC alone or in combination with unfractionated heparin or low-molecular-weight heparin (ie, bridging) is based upon an assessment of the risk of a thrombus developing within the next several days versus the risk of bleeding complications.</fragment>
				</section>
			</summary>
			<category term="C0249610" scheme="gov.nih.nlm.semanticType.phsu" label="OAC"/>
			<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
			<category term="C2825026" scheme="gov.nih.nlm.semanticType.phsu" label="unfractionated heparin"/>
			<category term="C3536766" scheme="gov.nih.nlm.semanticType.phsu" label="low-molecular-weight heparin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206021</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>In most patients with nonvalvular AF, the risk of stroke during the several days typically required to reach a therapeutic INR or therapeutic anticoagulation with dabigatran or rivaroxaban is very low.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206023</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>For patients deemed to be at high risk of thromboembolism (eg, remote cerebrovascular event/transient ischemic attack [TIA] or intracardiac thrombus, bioprosthetic valve, or mitral stenosis) and low risk of ICH, initiation of warfarin with a heparin bridging regimen is reasonable.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206026</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>Patients with nonvalvular AF who present with acute stroke have a relatively high risk of recurrent embolism and/or progressive ischemia (approximately 5 percent during the first two weeks).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206027</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>Although early use of heparin reduces the rate of recurrent embolism and/or progressive ischemia in some trials, this is balanced by an increased incidence of transformation to hemorrhagic stroke, especially in patients with large strokes.</fragment>
				</section>
			</summary>
			<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H10"/>
			<id>206028</id>
			<summary>
				<section label="Initiation of therapy" id="10">
					<fragment>The conclusion from these data is that there is no overall benefit to early heparin therapy, and we generally do not recommend heparin bridging in patients with acute stroke.</fragment>
				</section>
			</summary>
			<category term="C0399080" scheme="gov.nih.nlm.semanticType.topp" label="bridging"/>
			<category term="C0522794" scheme="gov.nih.nlm.semanticType.topp" label="heparin therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206033</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>An INR between 2.0 and 3.0 is recommended for most patients with nonvalvular AF who receive warfarin.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206035</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>The severity of stroke and the mortality rate in patients with nonvalvular AF are also increased when the INR is below 2.0.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206037</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>However, the BAFTA trial, in which the mean age of participants was 81 years, found that warfarin (target INR 2.0 to 3.0) was superior to aspirin (75 mg/day) for stroke prevention, with no difference in major bleeding between the two treatment arms.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C1277289" scheme="gov.nih.nlm.semanticType.topp" label="stroke prevention"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206049</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>In addition, patients with poor control had a significantly higher annual rate of stroke or systemic embolization than those with good control (2.1 versus 1.1 percent).</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206050</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>The importance of time in therapeutic range (TTR) was further emphasized in a secondary analysis from the ACTIVE-W trial of clopidogrel plus aspirin versus vitamin K antagonists (VKA) for patients with non-valvular AF.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonists"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206052</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>For example, in the analysis by participating country, an average TTR of 50 percent was needed to demonstrate any benefit of anticoagulant therapy versus clopidogrel plus aspirin.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H11"/>
			<id>206061</id>
			<summary>
				<section label="Warfarin, INR monitoring, and target INR" id="11">
					<fragment>After stabilization at a therapeutic level of warfarin, the INR should generally be monitored at least monthly, and more frequently if there has been a change in medication or diet as these may alter the effect of warfarin.</fragment>
				</section>
			</summary>
			<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H13"/>
			<id>206069</id>
			<summary>
				<section label="Temporary cessation of anticoagulation" id="13">
					<fragment>The discussion of the management of anticoagulant therapy in the patient undergoing percutaneous coronary intervention is found elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C1532338" scheme="gov.nih.nlm.semanticType.topp" label="percutaneous coronary intervention"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H14"/>
			<id>206070</id>
			<summary>
				<section label="Underutilization and discontinuation" id="14">
					<fragment>Despite the compelling evidence that warfarin reduces the risk of stroke in most patients with AF, such therapy continues to be underutilized.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H14"/>
			<id>206072</id>
			<summary>
				<section label="Underutilization and discontinuation" id="14">
					<fragment>Patients were less likely to be treated if they had paroxysmal AF or atrial flutter.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H15"/>
			<id>206084</id>
			<summary>
				<section label="Thromboembolism in anticoagulated patients" id="15">
					<fragment>While most ischemic stroke in AF patients is due to embolism of left atrial appendage thrombi, other stroke mechanisms should be considered.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H15"/>
			<id>206085</id>
			<summary>
				<section label="Thromboembolism in anticoagulated patients" id="15">
					<fragment>TEE evidence of complex aortic plaque.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842274"/>
			<id>206087</id>
			<summary>
				<section label="New oral anticoagulants" id="524842274">
					<fragment>Dabigatran (an oral direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (oral factor Xa inhibitors) have been compared to adjusted-dose warfarin (INR of 2.0 to 3.0) in large randomized trials of patients at intermediate to high risk of stroke.</fragment>
				</section>
			</summary>
			<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
			<category term="C2975435" scheme="gov.nih.nlm.semanticType.phsu" label="edoxaban"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842274"/>
			<id>206089</id>
			<summary>
				<section label="New oral anticoagulants" id="524842274">
					<fragment>Overall, the trials, discussed below, demonstrate equal or superior thromboembolism efficacy and major bleeding safety of these newer anticoagulants compared to warfarin.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842274"/>
			<id>206091</id>
			<summary>
				<section label="New oral anticoagulants" id="524842274">
					<fragment>Disadvantages include twice-daily dosing (dabigatran, apixaban), higher pharmaceutical cost, lack of an antidote/reversing agent, the potential need for dose adjustment in patients with chronic severe kidney disease, and lack of long-term safety and "real world" data.</fragment>
				</section>
			</summary>
			<category term="C0003295" scheme="gov.nih.nlm.semanticType.phsu" label="antidote"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842274"/>
			<id>206093</id>
			<summary>
				<section label="New oral anticoagulants" id="524842274">
					<fragment>Compared to warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban reduced the risk of stroke or systemic embolic events (relative risk [RR] 0.81, 95% CI 0.73-0.91), driven principally by a reduction in hemorrhagic stroke (RR 0.49, 95% CI 0.38-0.64).</fragment>
				</section>
			</summary>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C2975435" scheme="gov.nih.nlm.semanticType.phsu" label="edoxaban"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842274"/>
			<id>206098</id>
			<summary>
				<section label="New oral anticoagulants" id="524842274">
					<fragment>Further information on the use of these agents, including drug interactions, dosing in patients with chronic renal disease, and the need to take rivaroxaban with food, is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206113</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>The relative effects of dabigatran compared to warfarin on these events were consistent in patients with and without documented coronary artery disease.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206114</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>The finding of a higher rate of myocardial infarction in RE-LY was explored in a 2012 meta-analysis of seven trials (30,514 individuals) which compared dabigatran to either warfarin, enoxaparin, or placebo for stroke prophylaxis in AF, short-term prophylaxis of deep venous thrombosis, treatment of deep venous thrombosis or treatment of acute coronary syndrome.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0206460" scheme="gov.nih.nlm.semanticType.phsu" label="enoxaparin"/>
			<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206115</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>Dabigatran was associated with a significantly increased risk of myocardial infarction, cardiac death or unstable angina compared to the control group (odds ratio 1.27, 95% CI 1.00-1.61) and these results did not change after exclusion of three short-term trials.</fragment>
				</section>
			</summary>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206118</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>As the magnitude of the increase in risk of myocardial infarction is small and as the benefit for the prevention of a clinically more important end point (ischemic stroke) is larger with dabigatran, the findings of this meta-analysis do not change our recommendations for the use of dabigatran in AF.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206121</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>A 75 mg twice daily dose is available in the USA and is approved for patients with creatinine clearances of 15 to 30 ml/min based on pharmacokinetic modeling.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206125</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>In a statement issued by the United States Food and Drug Administration in November 2012 (and in the published Mini-Sentinel analysis), the rate of bleeding with dabigatran did not appear to be higher than that with warfarin in patients who were using either drug for the first time.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206127</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>In comparing 8936 and 4978 patients who received warfarin or dabigatran, respectively, there were no differences in the rates of stroke or systemic embolism during 10.5 months of follow-up.</fragment>
				</section>
			</summary>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4338483"/>
			<id>206130</id>
			<summary>
				<section label="Dabigatran" id="4338483">
					<fragment>A subgroup analysis of RE-LY including patients taking antiplatelet therapy is discussed below.</fragment>
				</section>
			</summary>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H358919860"/>
			<id>206135</id>
			<summary>
				<section label="Rivaroxaban" id="358919860">
					<fragment>In the ROCKET AF trial ), 14,264 AF patients at intermediate to high risk of stroke (mean CHADS2 score of 3.5) were randomly assigned to either rivaroxaban (20 mg daily or 15 mg daily in patients with a creatinine clearance of 30 to 49 mL/min) or warfarin (target INR 2.0-3.0).</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H147982962"/>
			<id>206146</id>
			<summary>
				<section label="Apixaban" id="147982962">
					<fragment>Patients with a creatinine greater than 2.5 mg/dL or a calculated eGFR of less than 25 mL/min were excluded from the ARISTOTLE trial.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H147982962"/>
			<id>206147</id>
			<summary>
				<section label="Apixaban" id="147982962">
					<fragment>The following analyses have been reported: A subgroup analysis was performed in the 3436 patients with prior stroke or transient ischemic attack (TIA).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H147982962"/>
			<id>206150</id>
			<summary>
				<section label="Apixaban" id="147982962">
					<fragment>Of interest, the absolute reduction in the primary end point with apixaban versus warfarin was greater in patients with compared to those without prior stroke or TIA (0.77 compared to 0.22 per 100 patient-years, respectively).</fragment>
				</section>
			</summary>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H88655099"/>
			<id>206159</id>
			<summary>
				<section label="Edoxaban" id="88655099">
					<fragment>A distinctive feature of this trial was that the assigned dose of novel anticoagulant was halved for a creatinine clearance of 30 to 50 mL/min or weight &lt;=60 kg or if the patient was taking a P-glycoprotein inhibitor (eg, verapamil, quinidine, or dronedarone).</fragment>
				</section>
			</summary>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0766326" scheme="gov.nih.nlm.semanticType.phsu" label="dronedarone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524842440"/>
			<id>206163</id>
			<summary>
				<section label="Reversal of anticoagulant effect" id="524842440">
					<fragment>An important concern, about the use of oral direct thrombin and factor Xa inhibitors, is that no antidote has been shown, in studies of patients taking these drugs, to cause immediate reversal of their anticoagulant effect.</fragment>
				</section>
			</summary>
			<category term="C0003295" scheme="gov.nih.nlm.semanticType.phsu" label="antidote"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H433859596"/>
			<id>206168</id>
			<summary>
				<section label="Transition from newer anticoagulants to warfarin" id="433859596">
					<fragment>As these newer agents have a relatively short period of clinical efficacy compared to warfarin, there is a concern that patients might not be adequately anticoagulated unless there is a period of drug overlap.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0185027" scheme="gov.nih.nlm.semanticType.topp" label="overlap"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H433859596"/>
			<id>206172</id>
			<summary>
				<section label="Transition from newer anticoagulants to warfarin" id="433859596">
					<fragment>Practitioners should also be aware that the newer agents can alter the international normalized ratio (INR), causing uncertainty as to when the patient is properly anticoagulated with warfarin.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H16"/>
			<id>206192</id>
			<summary>
				<section label="Alternatives to anticoagulant monotherapy" id="16">
					<fragment>Warfarin is superior to these alternatives in patients at high risk of stroke, while aspirin therapy is considered a reasonable option in patients at low thromboembolic risk.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206193</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>Aspirin has been compared to either warfarin or placebo and been shown to be less effective than the former and not clearly superior to the latter.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="Aspirin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206194</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>Thus, the evidence to support the use of aspirin for the prevention of thromboembolic events in patients with AF is very weak.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206195</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>Randomized trials have shown that aspirin is consistently and substantially less effective than warfarin in all AF patients with a CHADS2 score above 0.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206197</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>Patients treated with warfarin were significantly less likely to experience an ischemic stroke (2.0 versus 4.3 per 100 patient-years, hazard ratio 0.55, 95% CI 0.45-0.71);</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206199</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>It was concluded that treating 100 patients with warfarin rather than aspirin for one year would prevent 2.3 ischemic strokes.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206200</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>The issue of whether aspirin could be a reasonable choice in very low risk patients (CHADS2 = 0) has not been well addressed.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206203</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>Thus, for patients with no identified clinical risk factors for stroke, defined as a CHADS2 score of 0, aspirin is of uncertain benefit (or anticoagulant).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206204</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>This is consistent with the 2012 European Society of Cardiology guidelines for the management of AF, which concluded that the available evidence does not support the use of aspirin in most patients who are defined as a CHA2DS2-VASc of 0 or 1, as the risk of bleeding may exceed the small benefit.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206205</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>That document does recommend oral anticoagulant therapy for patients with a CHA2DS2-VASc score of 1.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="document"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206206</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>For those patients with CHADS2 score of 0 and a CHA2DS2-VASc score of 0, and who are willing to accept the risks of aspirin therapy in exchange for a likely small decrease in the risk of stroke, aspirin may be a reasonable choice.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4339005"/>
			<id>206210</id>
			<summary>
				<section label="Aspirin" id="4339005">
					<fragment>The use of aspirin for secondary prevention of cardiovascular disease in patients treated with warfarin for AF is discussed below.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206211</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>Two large randomized trials have investigated the safety and efficacy of dual antiplatelet therapy in patients with AF.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206212</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>ACTIVE W compared clopidogrel plus aspirin to warfarin and ACTIVE A compared clopidogrel plus aspirin to aspirin alone in patients who were not candidates for anticoagulation with a vitamin K antagonist.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206214</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>The primary end point in both trials was a composite outcome (the first occurrence of stroke, systemic [non-central nervous system] embolization, MI, or vascular death).</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
			<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206215</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>The ACTIVE W trial included 6706 patients who were randomly assigned to combined therapy with clopidogrel (75 mg/day) and aspirin (75 to 100 mg/day) or to oral anticoagulation with a vitamin K antagonist (target INR 2.0 to 3.0).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C2267235" scheme="gov.nih.nlm.semanticType.phsu" label="vitamin K antagonist"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206220</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>The ACTIVE A trial included 7554 patients with AF who were not candidates for warfarin anticoagulation and were randomly assigned to combined therapy with clopidogrel (75 mg/day) and aspirin (75 to 100 mg/day) or to aspirin alone at the same dose.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206222</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>Patients were excluded from participation in ACTIVE A if they had documented peptic ulcer disease in the previous six months, significant thrombocytopenia, prior ICH, or ongoing alcohol abuse.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206224</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>After a median follow-up period of 3.6 years, patients treated with clopidogrel plus aspirin had a significantly lower annual rate of the primary combined end point (6.8 versus 7.8 percent, relative risk [RR] 0.89, 95% CI 0.81-0.98), which was primarily driven by a reduction in stroke (2.4 versus 3.3 percent, RR 0.72, 95% CI 0.62-0.83).</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H19"/>
			<id>206228</id>
			<summary>
				<section label="Aspirin plus clopidogrel" id="19">
					<fragment>Dual antiplatelet therapy may be a reasonable alternative to therapy with aspirin alone in the occasional high-risk patient with AF who CANNOT be treated with anticoagulation.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H411109061"/>
			<id>206231</id>
			<summary>
				<section label="dose warfarin" id="411109061">
					<fragment>In contrast to adjusted-dose warfarin, low-dose warfarin (1.25 mg/day or target INR between 1.2 and 1.5) in combination with aspirin (300 to 325 mg/day) should not be used to reduce stroke risk in patients with non-valvular AF.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H411109157"/>
			<id>206234</id>
			<summary>
				<section label="Aspirin plus full dose warfarin" id="411109157">
					<fragment>The issue of whether combination of aspirin plus full dose warfarin might have greater efficacy than warfarin alone has not been well studied.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H411109157"/>
			<id>206235</id>
			<summary>
				<section label="Aspirin plus full dose warfarin" id="411109157">
					<fragment>In a post-hoc analysis of the SPORTIF trials, which included a high percentage of patients with cardiovascular disease or at high risk, combination therapy with warfarin (or ximelagatran) plus aspirin, in comparison to anticoagulant alone, did not reduce the rate of stroke or systemic embolism.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C0966370" scheme="gov.nih.nlm.semanticType.phsu" label="ximelagatran"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H411109157"/>
			<id>206236</id>
			<summary>
				<section label="Aspirin plus full dose warfarin" id="411109157">
					<fragment>However, patients may require aspirin (or other antiplatelet agent) for reasons such as the primary or secondary prevention of coronary artery disease, treatment of acute coronary syndrome, or after placement of an intracoronary stent.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agent"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H21"/>
			<id>206241</id>
			<summary>
				<section label="Nonpharmacologic alternatives" id="21">
					<fragment>Approaches that may be considered include the surgical atrial isolation/maze procedure in patients undergoing cardiac surgery for some other reason and pulmonary vein isolation by radiofrequency catheter ablation.</fragment>
				</section>
			</summary>
			<category term="C0162561" scheme="gov.nih.nlm.semanticType.topp" label="radiofrequency catheter ablation"/>
			<category term="C0162563" scheme="gov.nih.nlm.semanticType.topp" label="catheter ablation"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0547070" scheme="gov.nih.nlm.semanticType.topp" label="ablation"/>
			<category term="C2587206" scheme="gov.nih.nlm.semanticType.topp" label="maze procedure"/>
			<category term="C3544330" scheme="gov.nih.nlm.semanticType.topp" label="pulmonary vein isolation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H524844231"/>
			<id>206244</id>
			<summary>
				<section label="Patients with acute stroke" id="524844231">
					<fragment>Recommendations for the prevention of secondary embolism in AF patients with an acute stroke and for the antithrombotic management of patients with an acute embolic stroke are presented separately.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H652183"/>
			<id>206245</id>
			<summary>
				<section label="Patients with prior stroke or TIA" id="652183">
					<fragment>Among all known predictors of stroke in patients with AF, prior stroke or transient ischemic attack (TIA) is the strongest independent predictor.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H652183"/>
			<id>206246</id>
			<summary>
				<section label="Patients with prior stroke or TIA" id="652183">
					<fragment>In patients not treated with anticoagulant therapy, the annual rate is between 6 and 10 percent per year.</fragment>
				</section>
			</summary>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H25"/>
			<id>206248</id>
			<summary>
				<section label="Patients treated with rhythm control" id="25">
					<fragment>Patients treated with pharmacologic rhythm control have rates of thromboembolic events similar to those with rate control, as was shown in the RACE and AFFIRM trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H25"/>
			<id>206249</id>
			<summary>
				<section label="Patients treated with rhythm control" id="25">
					<fragment>This observation likely occurs for two reasons: recurrent episodes of AF are common and asymptomatic in up to 90 percent, and some patients have other reasons for thromboembolic risk, such as aortic plaque or left ventricular systolic dysfunction for which anticoagulation may be protective from clinical thromboembolism.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H25"/>
			<id>206250</id>
			<summary>
				<section label="Patients treated with rhythm control" id="25">
					<fragment>Based upon these findings, most patients with AF, regardless of whether a rate-control or rhythm-control strategy is chosen, should receive antithrombotic therapy.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H26"/>
			<id>206251</id>
			<summary>
				<section label="Patients with hyperthyroidism" id="26">
					<fragment>The role of anticoagulant therapy is less well defined in patients in whom the underlying disease associated with AF can be corrected, as in hyperthyroidism.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H26"/>
			<id>206255</id>
			<summary>
				<section label="Patients with hyperthyroidism" id="26">
					<fragment>Lower-than-expected warfarin doses are usually required, since hyperthyroidism is associated with increased clearance of vitamin K-dependent clotting factors.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206257</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>Combined therapy with aspirin and an anticoagulant may be reasonable in selected patients with coronary artery disease, especially those with acute coronary syndromes or those who have received coronary stents, for whom the potential benefits may outweigh the increased risk of hemorrhage.)</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="Combined therapy"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206258</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>The issue of whether aspirin is necessary for secondary prevention of cardiovascular disease in patients treated with anticoagulant for AF is discussed in detail elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206259</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>As discussed above, neither aspirin alone or in combination with clopidogrel is as effective as warfarin in preventing stroke.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="preventing"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206262</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>The impact of antiplatelet therapy on bleeding (and efficacy) outcomes in patients taking either warfarin or dabigatran was evaluated in a post hoc, subgroup analysis of the RE-LY trialaspirin or clopidogrel at some point during the study.</fragment>
				</section>
			</summary>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206263</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>Very few patients were taking two antiplatelet agents and individuals taking prasugrel or ticagrelor were not enrolled.</fragment>
				</section>
			</summary>
			<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agents"/>
			<category term="C1620287" scheme="gov.nih.nlm.semanticType.phsu" label="prasugrel"/>
			<category term="C1999375" scheme="gov.nih.nlm.semanticType.phsu" label="ticagrelor"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206264</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>The following findings were noted: In the comparison of dabigatran 110 mg twice daily to warfarin for the prevention of ischemic events, antiplatelet therapy did not significantly change the relative risk (dabigatran non-inferior to warfarin).</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206265</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>With regard to the outcome of major bleeding, the relative risk did not change significantly, but the crude rates of bleeding were higher in those receiving antiplatelet therapy (2.22 versus 2.81 and 3.84 versus 4.81 percent, comparing dabigatran 110 mg to warfarin in the no antiplatelet and antiplatelet groups, respectively).</fragment>
				</section>
			</summary>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H27"/>
			<id>206269</id>
			<summary>
				<section label="term antiplatelet therapy" id="27">
					<fragment>This subgroup analysis from RE-LY raises the possibility that in AF patients treated with both oral anticoagulant and antiplatelet therapy, dabigatran might be preferred to warfarin to reduce the absolute risk of major bleeding.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="C1097361" scheme="gov.nih.nlm.semanticType.phsu" label="LY"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="dabigatran"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H1304772709"/>
			<id>206270</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="1304772709">
					<fragment>Recommendations for the use of antithrombotic agents in patients with AF are available from the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, the European Society of Cardiology, and the American College of Chest Physicians.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1704311" scheme="gov.nih.nlm.semanticType.phsu" label="antithrombotic agents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H1304772709"/>
			<id>206275</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="1304772709">
					<fragment>A scientific advisory (Oral antithrombotic agents for the prevention of stroke in nonvalvular AF) from the American Heart Association/American Stroke Association was published in 2012.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C1704311" scheme="gov.nih.nlm.semanticType.phsu" label="antithrombotic agents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H1304772709"/>
			<id>206276</id>
			<summary>
				<section label="RECOMMENDATIONS OF OTHERS" id="1304772709">
					<fragment>It emphasized caution with the use of the newer agents in patients with chronic kidney disease and in those older than 80 years, as well as when used in combination with an antiplatelet agent.</fragment>
				</section>
			</summary>
			<category term="C0085826" scheme="gov.nih.nlm.semanticType.phsu" label="antiplatelet agent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206288</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Antithrombotic therapy with oral anticoagulant therapy is effective in reducing the risk of clinical systemic embolization in patients with nonvalvular atrial fibrillation (AF).</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0354604" scheme="gov.nih.nlm.semanticType.phsu" label="oral anticoagulant"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206291</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Aspirin has been compared to either warfarin or placebo and been shown to be less effective than warfarin and not clearly superior to aspirin.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="Aspirin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206292</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Combination antiplatelet therapy with clopidogrel plus aspirin is superior to aspirin but remains inferior to warfarin in terms of efficacy, and is associated with a higher rate of bleeding than aspirin alone.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C1096021" scheme="gov.nih.nlm.semanticType.topp" label="antiplatelet therapy"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206298</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Our recommendations for antithrombotic therapy in patients with nonvalvular AF are as follows: For patients with CHADS2 and CHA2DS2-VASc scores of 0, we suggest no antithrombotic therapy rather than aspirin.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206305</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>For the uncommon patient who cannot take anticoagulant therapy for reasons other than bleeding risk, we suggest aspirin 75 to 100 mg daily plus clopidogrel 75 mg daily, rather than aspirin alone.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0070166" scheme="gov.nih.nlm.semanticType.phsu" label="clopidogrel"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206306</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>In patients with AF for whom anticoagulant therapy is chosen, we suggest an oral direct thrombin inhibitor or a factor Xa inhibitor rather than warfarin.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0150457" scheme="gov.nih.nlm.semanticType.topp" label="anticoagulant therapy"/>
			<category term="C0209655" scheme="gov.nih.nlm.semanticType.phsu" label="Xa"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206309</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Dabigatran, rivaroxaban, and apixaban should not be used in patients with severely impaired renal function (eGFR less than 30 mL/min/1.73m2 for dabigatran and rivaroxaban; less than 25 mL/min/1.73m2 for apixaban), those with prosthetic heart valves, those with mitral stenosis, or those with other valvular lesions associated with moderate to severe heart failure that might lead to valve replacement in the near future.</fragment>
				</section>
			</summary>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="rivaroxaban"/>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="C2348066" scheme="gov.nih.nlm.semanticType.phsu" label="Dabigatran"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H485506384"/>
			<id>206313</id>
			<summary>
				<section label="Indications for and choice of therapy" id="485506384">
					<fragment>Patients with chronic severe kidney disease, whose estimated glomerular filtration rate is less than 30 mL/min/1.73m2 (less than 25 mL/min/1.73m2 for apixaban.</fragment>
				</section>
			</summary>
			<category term="C1831808" scheme="gov.nih.nlm.semanticType.phsu" label="apixaban"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4535204"/>
			<id>206319</id>
			<summary>
				<section label="Dosing issues" id="4535204">
					<fragment>For patients whose time in therapeutic range cannot be increased above 60 percent, consideration should be given to using another anticoagulant.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1031#H4535204"/>
			<id>206325</id>
			<summary>
				<section label="Dosing issues" id="4535204">
					<fragment>Rivaroxaban should be prescribed at a dose of 20 mg daily for those with a creatinine clearance of at least 50 mL/min or 15 mg daily in patients with a creatinine clearance of 30 to 49 mL/min.</fragment>
				</section>
			</summary>
			<category term="C1739768" scheme="gov.nih.nlm.semanticType.phsu" label="Rivaroxaban"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
